Europe PMC Funders Author Manuscripts

DATA AND ANALYSES

Comparison 1

Any supplements containing iron versus same supplements without iron or no treatment/ placebo (no iron or placebo)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Low birthweight (less than 2500 g) (ALL)	11	8480	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.68, 0.97]
2 Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by gestational age at the start of supplementation	11	8480	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.68, 0.97]
2.1 Early gestational age (supplementation started before 20 weeks' gestation or prior to pregnancy)	6	5379	Risk Ratio (M-H, Random, 95% CI)	0.74 [0.55, 1.00]
2.2 Late gestational age (supplementation started at 20 weeks of gestation or later)	3	665	Risk Ratio (M-H, Random, 95% CI)	1.05 [0.50, 2.19]
2.3 Unspecified or mixed gestational age at the start of supplementation	2	2436	Risk Ratio (M-H, Random, 95% CI)	0.87 [0.61, 1.24]
3 Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by anaemia status at the start of supplementation	11	8480	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.68, 0.97]
3.1 Anaemic at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
3.2 Non-anaemic at the start of supplementation	8	4710	Risk Ratio (M-H, Random, 95% CI)	0.75 [0.49, 1.16]
3.3 Unspecified or mixed anaemia status	3	3770	Risk Ratio (M-H, Random, 95% CI)	0.82 [0.72, 0.94]
4 Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by dose of iron	11	8480	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.68, 0.97]
4.1 Low daily dose of iron (30 mg or less of elemental iron)	4	1031	Risk Ratio (M-H, Random, 95% CI)	0.57 [0.23, 1.41]
4.2 Medium daily dose of iron (more than 30 mg and less than 60 mg elemental iron)	1	727	Risk Ratio (M-H, Random, 95% CI)	1.21 [0.57, 2.54]
4.3 Higher daily dose of iron (60 mg elemental iron or more)	6	6722	Risk Ratio (M-H, Random, 95% CI)	0.83 [0.73, 0.94]
5 Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by malarial status of setting	11	8480	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.68, 0.97]
5.1 Malarial setting	5	4645	Risk Ratio (M-H, Random, 95% CI)	0.83 [0.73, 0.94]
5.2 Non-malarial setting	6	3835	Risk Ratio (M-H, Random, 95% CI)	0.70 [0.40, 1.24]
6 Birthweight (g) (ALL)	14	9385	Mean Difference (IV, Random, 95% CI)	30.81 [5.94, 55.68]
7 Birthweight (g): SUBGROUP ANALYSIS by gestational age at the start of supplementation	14	9385	Mean Difference (IV, Random, 95% CI)	30.81 [5.94, 55.68]
7.1 Early gestational age (supplementation started before 20 weeks' gestation or prior to pregnancy)	10	6378	Mean Difference (IV, Random, 95% CI)	38.63 [3.26, 73.99]
7.2 Late gestational age (supplementation started at 20 weeks of gestation or later)	3	681	Mean Difference (IV, Random, 95% CI)	−0.19 [−77.46, 77.08]
7.3 Unspecified or mixed gestational age at the start of supplementation	1	2326	Mean Difference (IV, Random, 95% CI)	20.20 [−15.13, 55.53]
8 Birthweight (g): SUBGROUP ANALYSIS by anaemia status at the start of supplementation	14	9385	Mean Difference (IV, Random, 95% CI)	30.81 [5.94, 55.68]

Europe PMC Funders Author Manuscripts

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
8.1 Anaemic at start of supplementation	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
8.2 Non-anaemic at the start of supplementation	10	5426	Mean Difference (IV, Random, 95% CI)	31.13 [−8.90, 71.15]
8.3 Unspecified or mixed anaemia status	4	3959	Mean Difference (IV, Random, 95% CI)	33.02 [3.65, 62.38]
9 Birthweight (g): SUBGROUP ANALYSIS by dose of iron	14	9385	Mean Difference (IV, Random, 95% CI)	30.63 [7.05, 54.22]
9.1 Low daily dose (30 mg or less of elemental iron)	6	1902	Mean Difference (IV, Random, 95% CI)	52.87 [−11.51, 117.26]
9.2 Medium daily dose (more than 30 mg and less than 60 mg elemental iron)	1	727	Mean Difference (IV, Random, 95% CI)	10.0 [−51.92, 71.92]
9.3 Higher daily dose (60 mg elemental iron or more)	8	6756	Mean Difference (IV, Random, 95% CI)	27.56 [2.59, 52.54]
10 Birthweight (g): SUBGROUP ANALYSIS by malarial status of setting	14	9385	Mean Difference (IV, Random, 95% CI)	30.81 [5.94, 55.68]
10.1 Malarial setting	6	5443	Mean Difference (IV, Random, 95% CI)	33.48 [10.58, 56.37]
10.2 Non-malarial setting	8	3942	Mean Difference (IV, Random, 95% CI)	25.96 [−42.06, 93.97]
11 Premature birth (less than 37 weeks of gestation) (ALL)	13	10148	Risk Ratio (M-H, Random, 95% CI)	0.88 [0.77, 1.01]
12 Premature birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by gestational age at the start of supplementation	13	10148	Risk Ratio (M-H, Random, 95% CI)	0.88 [0.77, 1.01]
12.1 Early gestational age (supplementation started before 20 weeks' gestation or prior to pregnancy)	10	7345	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.80, 1.08]
12.2 Late gestational age (supplementation started at 20 weeks of gestation or later)	2	477	Risk Ratio (M-H, Random, 95% CI)	0.58 [0.29, 1.13]
12.3 Unspecified or mixed 'gestational age at the start of supplementation	1	2326	Risk Ratio (M-H, Random, 95% CI)	0.79 [0.57, 1.09]
13 Premature birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by anaemia status at the start of supplementation	13	10148	Risk Ratio (M-H, Random, 95% CI)	0.88 [0.77, 1.01]
13.1 Anaemic at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
13.2 Non-anaemic at the start of supplementation	10	5699	Risk Ratio (M-H, Random, 95% CI)	0.74 [0.59, 0.94]
13.3 Unspecified/ mixed anaemia status	3	4449	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.81, 1.14]
14 Premature birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by dose of iron	13	10148	Risk Ratio (M-H, Random, 95% CI)	0.88 [0.77, 1.01]
14.1 Low daily dose (30 mg or less of elemental iron)	5	1817	Risk Ratio (M-H, Random, 95% CI)	0.70 [0.50, 0.98]
14.2 Medium daily dose (more than 30 mg and less than 60 mg elemental iron)	1	727	Risk Ratio (M-H, Random, 95% CI)	1.26 [0.62, 2.56]
14.3 Higher daily dose (60 mg elemental iron or more)	7	7604	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.78, 1.06]
15 Premature birth (less 37 weeks of gestation): SUBGROUP ANALYSIS by malarial status of setting	13	10148	Risk Ratio (M-H, Random, 95% CI)	0.88 [0.77, 1.01]
15.1 Malarial setting	7	6406	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.82, 1.11]
15.2 Non-malarial setting	6	3742	Risk Ratio (M-H, Random, 95% CI)	0.69 [0.52, 0.91]
16 Neonatal death (within 28 days after delivery) (ALL)	4	7465	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.68, 1.19]
17 Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by gestational age at the start of supplementation	4	7465	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.68, 1.19]
17.1 Early gestational age (supplementation started before 20 weeks' gestation or prior to pregnancy)	3	4970	Risk Ratio (M-H, Random, 95% CI)	1.01 [0.67, 1.53]

Europe PMC Funders Author Manuscripts

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
17.2 Late gestational age (supplementation started at 20 weeks of gestation or later)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
17.3 Unspecified or mixed gestational age at the start of supplementation	1	2495	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.56, 1.19]
18 Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by anaemia status at the start of supplementation	4	7465	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.68, 1.19]
18.1 Anaemic at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
18.2 Non-anaemic at the start of supplementation	2	3421	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.37, 2.39]
18.3 Unspecified or mixed anaemia status	2	4044	Risk Ratio (M-H, Random, 95% CI)	0.88 [0.65, 1.19]
19 Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by dose of iron	4	7465	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.68, 1.19]
19.1 Low daily dose (30 mg or less of elemental iron)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
19.2 Medium daily dose (more than 30 mg and less than 60 mg elemental iron)	1	727	Risk Ratio (M-H, Random, 95% CI)	0.48 [0.12, 1.91]
19.3 Higher daily dose (60 mg elemental iron or more)	3	6738	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.69, 1.23]
20 Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by malarial status of setting	4	7465	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.68, 1.19]
20.1 Malarial setting	3	4771	Risk Ratio (M-H, Random, 95% CI)	0.85 [0.63, 1.15]
20.2 Non-malarial setting	1	2694	Risk Ratio (M-H, Random, 95% CI)	1.32 [0.58, 3.00]
21 Congenital anomalies (ALL)	3	2702	Risk Ratio (M-H, Random, 95% CI)	0.86 [0.55, 1.35]
22 Congenital anomalies: SUBGROUP ANALYSIS by gestational age at the start of supplementation)	3	2702	Risk Ratio (M-H, Random, 95% CI)	0.86 [0.55, 1.35]
22.1 Early gestational age (supplementation started before 20 weeks' gestation or prior to pregnancy)	3	2702	Risk Ratio (M-H, Random, 95% CI)	0.86 [0.55, 1.35]
22.2 Late gestational age (supplementation started at 20 weeks of gestation or later)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
22.3 Unspecified or mixed gestational age at the start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
23 Congenital anomalies: SUBGROUP ANALYSIS by anaemia status at the start of supplementation	3	2702	Risk Ratio (M-H, Random, 95% CI)	0.86 [0.55, 1.35]
23.1 Anaemic at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
23.2 Non-anaemic at the start of supplementation	1	300	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
23.3 Unspecified or mixed anaemia status	2	2402	Risk Ratio (M-H, Random, 95% CI)	0.86 [0.55, 1.35]
24 Congenital anomalies: SUBGROUP ANALYSIS by dose of iron	3	2702	Risk Ratio (M-H, Random, 95% CI)	0.86 [0.55, 1.35]
24.1 Low daily dose (30 mg or less of elemental iron)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
24.2 Medium daily dose (more than 30 mg and less than 60 mg elemental iron)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
24.3 Higher daily dose (60 mg elemental iron or more)	3	2702	Risk Ratio (M-H, Random, 95% CI)	0.86 [0.55, 1.35]
25 Congenital anomalies: SUBGROUP ANALYSIS by malarial status of setting	3	2699	Risk Ratio (M-H, Random, 95% CI)	0.87 [0.60, 1.26]
25.1 Malarial setting	3	2699	Risk Ratio (M-H, Random, 95% CI)	0.87 [0.60, 1.26]
25.2 Non-malarial setting	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]

Europe PMC Funders Author Manuscripts

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
26 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more) (ALL)	14	2199	Risk Ratio (M-H, Random, 95% CI)	0.30 [0.19, 0.46]
27 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation):	14	2199	Risk Ratio (M-H, Random, 95% CI)	0.30 [0.19, 0.46]
27.1 Early gestational age (supplementation started before 20 weeks' gestation o prior to pregnancy)	7	749	Risk Ratio (M-H, Random, 95% CI)	0.28 [0.12, 0.70]
27.2 Late gestational age (supplementation started at 20 weeks of gestation or later)	5	1178	Risk Ratio (M-H, Random, 95% CI)	0.36 [0.22, 0.61]
27.3 Unspecified or mixed gestational age	2	272	Risk Ratio (M-H, Random, 95% CI)	0.08 [0.01, 0.59]
28 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation)	14	2199	Risk Ratio (M-H, Random, 95% CI)	0.30 [0.19, 0.46]
28.1 Anaemic at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
28.2 Non-anaemic at the start of supplementation	8	1295	Risk Ratio (M-H, Random, 95% CI)	0.32 [0.16, 0.64]
28.3 Unspecified or mixed anaemia status	6	904	Risk Ratio (M-H, Random, 95% CI)	0.24 [0.12, 0.49]
29 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron)	14	2199	Risk Ratio (M-H, Random, 95% CI)	0.30 [0.19, 0.46]
29.1 Low daily dose (30 mg or less of elemental iron)	3	590	Risk Ratio (M-H, Random, 95% CI)	0.49 [0.24, 1.03]
29.2 Medium daily dose (more than 30 mg and less than 60 mg elemental iron)	1	69	Risk Ratio (M-H, Random, 95% CI)	0.21 [0.06, 0.73]
29.3 Higher daily dose (60 mg elemental iron or more)	10	1540	Risk Ratio (M-H, Random, 95% CI)	0.25 [0.14, 0.45]
30 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting)	14	2199	Risk Ratio (M-H, Random, 95% CI)	0.30 [0.19, 0.46]
30.1 Malarial setting	3	530	Risk Ratio (M-H, Random, 95% CI)	0.61 [0.45, 0.82]
30.2 Non-malarial setting	11	1669	Risk Ratio (M-H, Random, 95% CI)	0.18 [0.10, 0.34]
31 Maternal iron deficiency at term (as defined by as defined by trialists, based on any indicator of iron status at 37 weeks's gestation or more) (ALL)	7	1256	Risk Ratio (M-H, Random, 95% CI)	0.43 [0.27, 0.66]
32 Maternal iron deficiency at term (as defined by as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation	7	1256	Risk Ratio (M-H, Random, 95% CI)	0.43 [0.27, 0.66]
32.1 Early gestational age (supplementation started before 20 weeks' gestation or prior to pregnancy)	4	653	Risk Ratio (M-H, Random, 95% CI)	0.45 [0.22, 0.93]
32.2 Late gestational age (supplementation started at 20 weeks of gestation or later)	3	603	Risk Ratio (M-H, Random, 95% CI)	0.36 [0.18, 0.72]
32.3 Unspecified or mixed gestational age	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
33 Maternal iron deficiency at term (as defined by as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation	7	1256	Risk Ratio (M-H, Random, 95% CI)	0.43 [0.27, 0.66]
33.1 Anaemic at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
33.2 Non-anaemic at the start of supplementation	5	1092	Risk Ratio (M-H, Random, 95% CI)	0.56 [0.39, 0.82]

Europe PMC Funders Author Manuscripts

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
33.3 Unspecified/ mixed anaemia status	2	164	Risk Ratio (M-H, Random, 95% CI)	0.14 [0.07, 0.29]
34 Maternal iron deficiency at term (as defined by as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dos of iron	7	1256	Risk Ratio (M-H, Random, 95% CI)	0.43 [0.27, 0.66]
34.1 Low daily dose (30 mg or less of elemental iron)	3	703	Risk Ratio (M-H, Random, 95% CI)	0.52 [0.34, 0.78]
34.2 Medium daily dose (more than 30 mg and less than 60 mg elemental iron)	1	241	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.73, 1.17]
34.3 Higher daily dose (60 mg elemental iron or more)	3	312	Risk Ratio (M-H, Random, 95% CI)	0.21 [0.10, 0.41]
35 Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting	7	1256	Risk Ratio (M-H, Random, 95% CI)	0.43 [0.27, 0.66]
35.1 Malarial setting	2	192	Risk Ratio (M-H, Random, 95% CI)	0.28 [0.15, 0.53]
35.2 Non-malarial setting	5	1064	Risk Ratio (M-H, Random, 95% CI)	0.49 [0.30, 0.78]
36 Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicators at 37 weeks' gestation or more) (ALL)	6	1088	Risk Ratio (M-H, Random, 95% CI)	0.33 [0.16, 0.69]
37 Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicators at 37 weeks' gestation): SUBGROUP ANALYSIS by gestational age at the start of supplementation	6	1088	Risk Ratio (M-H, Random, 95% CI)	0.33 [0.16, 0.69]
37.1 Early gestational age (supplementation started before 20 weeks' gestation or prior to pregnancy)	4	660	Risk Ratio (M-H, Random, 95% CI)	0.39 [0.13, 1.11]
37.2 Late gestational age (supplementation started at 20 weeks of gestation or later)	2	428	Risk Ratio (M-H, Random, 95% CI)	0.25 [0.11, 0.58]
37.3 Unspecified or mixed gestational age	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
38 Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicators at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation	6	1088	Risk Ratio (M-H, Random, 95% CI)	0.33 [0.16, 0.69]
38.1 Anaemic at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
38.2 Non-anaemic at the start of supplementation	5	968	Risk Ratio (M-H, Random, 95% CI)	0.39 [0.20, 0.74]
38.3 Unspecified or mixed anaemia status	1	120	Risk Ratio (M-H, Random, 95% CI)	0.04 [0.00, 0.72]
39 Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicators at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron	6	1088	Risk Ratio (M-H, Random, 95% CI)	0.33 [0.16, 0.69]
39.1 Low daily dose (30 mg or less of elemental iron)	3	579	Risk Ratio (M-H, Random, 95% CI)	0.38 [0.13, 1.11]
39.2 Medium daily dose (more than 30 mg and less than 60 mg elemental iron)	1	241	Risk Ratio (M-H, Random, 95% CI)	0.34 [0.16, 0.70]
39.3 Higher daily dose (60 mg elemental iron or more)	2	268	Risk Ratio (M-H, Random, 95% CI)	0.04 [0.00, 0.72]
40 Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicators at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting	6	1088	Risk Ratio (M-H, Random, 95% CI)	0.33 [0.16, 0.69]
40.1 Malarial setting	1	148	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
40.2 Non-malarial setting	5	940	Risk Ratio (M-H, Random, 95% CI)	0.33 [0.16, 0.69]

Europe PMC Funders Author Manuscripts

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
41 Maternal death (death while pregnant or within 42 days of termination of pregnancy) (ALL)	1	47	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
42 Side effects (any reported throughout the intervention period) (ALL)	11	4418	Risk Ratio (M-H, Random, 95% CI)	2.36 [0.96, 5.82]
43 Side effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by gestational age at the start of supplementation:	11	4418	Risk Ratio (M-H, Random, 95% CI)	2.43 [1.05, 5.63]
43.1 Early gestational age (supplementation started before 20 weeks' gestation or prior to pregnancy)	5	3181	Risk Ratio (M-H, Random, 95% CI)	2.44 [0.34, 17.39]
43.2 Late gestational age (supplementation started at 20 weeks of gestation or later)	5	1032	Risk Ratio (M-H, Random, 95% CI)	1.43 [0.89, 2.29]
43.3 Unspecified or mixed gestational age	1	205	Risk Ratio (M-H, Random, 95% CI)	62.79 [3.89, 1013.31]
44 Side effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by anaemia status at the start of supplementation	11	4418	Risk Ratio (M-H, Random, 95% CI)	2.43 [1.05, 5.63]
44.1 Anaemic at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
44.2 Non-anaemic at the start of supplementation	7	3643	Risk Ratio (M-H, Random, 95% CI)	1.87 [0.64, 5.45]
44.3 Unspecified or mixed anaemia status	4	775	Risk Ratio (M-H, Random, 95% CI)	5.16 [0.78, 34.29]
45 Side effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by dose of iron	11	4418	Risk Ratio (M-H, Random, 95% CI)	2.36 [1.06, 5.24]
45.1 Low daily dose (30 mg or less of elemental iron)	5	973	Risk Ratio (M-H, Random, 95% CI)	1.01 [0.84, 1.21]
45.2 Medium daily dose (more than 30 mg and less than 60 mg elemental iron)	2	225	Risk Ratio (M-H, Random, 95% CI)	2.00 [0.66, 6.02]
45.3 Higher daily dose (60 mg elemental iron or more)	6	3220	Risk Ratio (M-H, Random, 95% CI)	6.52 [1.13, 37.69]
46 Side effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by malarial status of setting	11	4418	Risk Ratio (M-H, Random, 95% CI)	2.43 [1.05, 5.63]
46.1 Malarial setting	1	205	Risk Ratio (M-H, Random, 95% CI)	62.79 [3.89, 1013.31]
46.2 Non-malarial setting	10	4213	Risk Ratio (M-H, Random, 95% CI)	2.02 [0.88, 4.65]
47 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L) (ALL)	9	2125	Risk Ratio (M-H, Random, 95% CI)	0.22 [0.01, 3.20]
48 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by gestational age at the start of supplementation	9	2125	Risk Ratio (M-H, Random, 95% CI)	0.22 [0.01, 3.20]
48.1 Early gestational age (supplementation started before 20 weeks' gestation o prior to pregnancy)	5	1417	Risk Ratio (M-H, Random, 95% CI)	0.06 [0.01, 0.47]
48.2 Late gestational age (supplementation started at 20 weeks of gestation or later)	3	559	Risk Ratio (M-H, Random, 95% CI)	0.48 [0.00, 46.15]
48.3 Unspecified or mixed gestational age	1	149	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
49 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by anaemia status at the start of supplementation	9	2125	Risk Ratio (M-H, Random, 95% CI)	0.22 [0.01, 3.20]
49.1 Anaemic at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
49.2 Non-anaemic at the start of supplementation	5	1394	Risk Ratio (M-H, Random, 95% CI)	4.98 [0.24, 103.01]
49.3 Unspecified or mixed anaemia status	4	731	Risk Ratio (M-H, Random, 95% CI)	0.06 [0.01, 0.30]
50 Maternal severe anaemia at any time during second and third trimester (Hb less	9	2125	Risk Ratio (M-H, Random, 95% CI)	0.22 [0.01, 3.20]

Europe PMC Funders Author Manuscripts

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
than 70 g/L): SUBGROUP ANALYSIS by dose of iron				
50.1 Low daily dose (30 mg or less of elemental iron)	3	654	Risk Ratio (M-H, Random, 95% CI)	4.98 [0.24, 103.01]
50.2 Medium daily dose (more than 30 mg and less than 60 mg elemental iron)	1	727	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
50.3 Higher daily dose (60 mg elemental iron or more)	5	744	Risk Ratio (M-H, Random, 95% CI)	0.06 [0.01, 0.30]
51 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by malarial status of setting	9	2125	Risk Ratio (M-H, Random, 95% CI)	0.22 [0.01, 3.20]
51.1 Malarial setting	3	1102	Risk Ratio (M-H, Random, 95% CI)	0.06 [0.01, 0.30]
51.2 Non-malarial setting	6	1023	Risk Ratio (M-H, Random, 95% CI)	4.98 [0.24, 103.01]
52 Maternal clinical malaria	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
53 Infection during pregnancy (including urinary tract infections) (ALL)	2	3421	Risk Ratio (M-H, Random, 95% CI)	1.16 [0.83, 1.63]
54 Infection during pregnancy (including urinary tract infections): SUBGROUP ANALYSIS by gestational age at the start of supplementation	2	3421	Risk Ratio (M-H, Random, 95% CI)	1.16 [0.83, 1.63]
54.1 Early gestational age (supplementation started before 20 weeks' gestation or prior to pregnancy)	2	3421	Risk Ratio (M-H, Random, 95% CI)	1.16 [0.83, 1.63]
54.2 Late gestational age (supplementation started at 20 weeks of gestation or later)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
54.3 Unspecified or mixed gestational age	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
55 Infection during pregnancy (including urinary tract infections): SUBGROUP ANALYSIS by anaemia status at the start of supplementation	2	3421	Risk Ratio (M-H, Random, 95% CI)	1.16 [0.83, 1.63]
55.1 Anaemic at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
55.2 Non-anaemic at the start of supplementation	2	3421	Risk Ratio (M-H, Random, 95% CI)	1.16 [0.83, 1.63]
55.3 Unspecified or mixed anaemia status	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
56 Infection during pregnancy (including urinary tract infections): SUBGROUP ANALYSIS by dose of iron	2	3421	Risk Ratio (M-H, Random, 95% CI)	1.16 [0.83, 1.63]
56.1 Low daily dose (30 mg or less of elemental iron)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
56.2 Medium daily dose (more than 30 mg and less than 60 mg elemental iron)	1	727	Risk Ratio (M-H, Random, 95% CI)	1.21 [0.33, 4.46]
56.3 Higher daily dose (60 mg elemental iron or more)	1	2694	Risk Ratio (M-H, Random, 95% CI)	1.16 [0.82, 1.65]
57 Infection during pregnancy (including urinary tract infections): SUBGROUP ANALYSIS by malarial status of setting	2	3421	Risk Ratio (M-H, Random, 95% CI)	1.16 [0.83, 1.63]
57.1 Malarial setting	1	727	Risk Ratio (M-H, Random, 95% CI)	1.21 [0.33, 4.46]
57.2 Non-malarial setting	1	2694	Risk Ratio (M-H, Random, 95% CI)	1.16 [0.82, 1.65]
58 Very low birthweight (less than 1500 g) (ALL)	5	2687	Risk Ratio (M-H, Random, 95% CI)	0.73 [0.31, 1.74]
59 Very premature birth (less than 34 weeks' gestation) (ALL)	5	3743	Risk Ratio (M-H, Random, 95% CI)	0.51 [0.29, 0.91]
60 Infant Hb concentration within the first 6 months (in g/L counting the last reported measure after birth within this period) (ALL)	2	533	Mean Difference (IV, Random, 95% CI)	−1.25 [−8.10, 5.59]
61 Infant serum ferritin concentration within first 6 months (in μg/L counting the last	1	197	Mean Difference (IV, Random, 95% CI)	11.0 [4.37, 17.63]

Europe PMC Funders Author Manuscripts

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
reported measure after birth within this period) (ALL)				
62 Admission to special care unit (ALL)	2	2805	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.73, 1.23]
63 Maternal anaemia at or near term (Hb less than 110 g/L at 34 weeks' gestation or more) (ALL)	15	4893	Risk Ratio (M-H, Random, 95% CI)	0.30 [0.19, 0.45]
64 Maternal iron deficiency at or near term (as defined by as defined by trialists, based on any indicator of iron status at 34 weeks's gestation or more)) (ALL)	7	1256	Risk Ratio (M-H, Random, 95% CI)	0.43 [0.27, 0.66]
65 Maternal iron-deficiency anaemia at or near term (Hb less than 110 g/L and at least one additional laboratory indicators at 34 weeks' gestation or more) (ALL)	6	1088	Risk Ratio (M-H, Random, 95% CI)	0.33 [0.16, 0.69]
66 Maternal Hb concentration at or near term (in g/L, at 34 weeks' gestation or more) (ALL)	19	3704	Mean Difference (IV, Random, 95% CI)	8.88 [6.96, 10.80]
67 Maternal Hb concentration within 6 wk postpartum (in g/L) (ALL)	7	956	Mean Difference (IV, Random, 95% CI)	7.61 [5.50, 9.72]
68 Maternal high haemoglobin concentrations during second or third trimester (Hb more than 130 g/L) (ALL)	10	4882	Risk Ratio (M-H, Random, 95% CI)	2.26 [1.40, 3.66]
69 Maternal high haemoglobin concentrations at or near term (Hb more than 130 g/L at 34 weeks' gestation or more) (ALL)	9	4850	Risk Ratio (M-H, Random, 95% CI)	3.08 [1.28, 7.41]
70 Maternal severe anaemia at or near term (Hb less than 70 g/L at 34 weeks' gestation or more) (ALL)	8	1819	Risk Ratio (M-H, Random, 95% CI)	0.47 [0.01, 44.11]
71 Severe anaemia at postpartum (Hb less than 80 g/L) (ALL)	8	1339	Risk Ratio (M-H, Random, 95% CI)	0.04 [0.01, 0.28]
72 Moderate anaemia at postpartum (Hb more than 80 g/L and less than 110 g/L) (ALL)	3	766	Risk Ratio (M-H, Random, 95% CI)	0.55 [0.12, 2.51]
73 Puerperal infection (ALL)	4	4374	Risk Ratio (M-H, Random, 95% CI)	0.68 [0.50, 0.92]
74 Antepartum haemorrhage (ALL)	2	1157	Risk Ratio (M-H, Random, 95% CI)	1.48 [0.51, 4.31]
75 Postpartum haemorrhage (ALL)	4	1488	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.59, 1.49]
76 Transfusion provided (ALL)	3	3453	Risk Ratio (M-H, Random, 95% CI)	0.61 [0.38, 0.96]
77 Diarrhoea (ALL)	3	1088	Risk Ratio (M-H, Random, 95% CI)	0.55 [0.32, 0.93]
78 Constipation (ALL)	4	1495	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.62, 1.43]
79 Nausea (ALL)	4	1377	Risk Ratio (M-H, Random, 95% CI)	1.21 [0.72, 2.03]
80 Heartburn (ALL)	3	1323	Risk Ratio (M-H, Random, 95% CI)	1.19 [0.86, 1.66]
81 Vomiting (ALL)	4	1392	Risk Ratio (M-H, Random, 95% CI)	0.88 [0.59, 1.30]
82 Maternal wellbeing/satisfaction (ALL)	2	2604	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.91, 1.09]
83 Placental abruption (ALL)	3	2951	Risk Ratio (M-H, Random, 95% CI)	1.41 [0.56, 3.59]
84 Premature rupture of membranes (ALL)	2	1509	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.72, 1.24]
85 Pre-eclampsia (ALL)	4	1704	Risk Ratio (M-H, Random, 95% CI)	1.63 [0.87, 3.07]

Europe PMC Funders Author Manuscripts

Comparison 2

Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Low birthweight (less than 2500 g) (ALL)	2	1311	Risk Ratio (M-H, Random, 95% CI)	1.07 [0.31, 3.74]
2 Birthweight (ALL)	2	1365	Mean Difference (IV, Random, 95% CI)	57.73 [7.66, 107.79]
3 Premature birth (less than 37 weeks of gestation) (ALL)	3	1497	Risk Ratio (M-H, Random, 95% CI)	1.55 [0.40, 6.00]
4 Premature birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by gestation at the start of supplementation	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
4.1 Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation	2	1366	Risk Ratio (M-H, Random, 95% CI)	1.55 [0.40, 6.00]
4.2 Late gestational age (supplementation started at 20 weeks of gestation or later)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
4.3 Unspecified or mixed gestational age at start of supplementation	1	44	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
5 Premature birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by anaemia status at the start of supplementation	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
5.1 Anaemic at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
5.2 Non-anaemic at the start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
5.3 Unspecified or mixed anaemic status at start of supplementation	3	1497	Risk Ratio (M-H, Random, 95% CI)	1.55 [0.40, 6.00]
6 Premature birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by dose of iron	3	1497	Risk Ratio (M-H, Random, 95% CI)	1.55 [0.40, 6.00]
6.1 Low daily dose (30 mg elemental iron or less)	1	131	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
6.2 Medium daily dose (31 to 59 mg elemental iron)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
6.3 Higher daily dose (60 mg elemental iron and above)	2	1366	Risk Ratio (M-H, Random, 95% CI)	1.55 [0.40, 6.00]
7 Premature birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by malarial status of settings	3	1497	Risk Ratio (M-H, Random, 95% CI)	1.55 [0.40, 6.00]
7.1 Malarial setting	2	1449	Risk Ratio (M-H, Random, 95% CI)	1.13 [0.92, 1.39]
7.2 Non-malarial setting	1	48	Risk Ratio (M-H, Random, 95% CI)	7.00 [0.38, 128.61]
8 Neonatal death (within 28 days after delivery) (ALL)	3	1793	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.51, 1.30]
9 Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by gestation at the start of supplementation	3	1793	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.51, 1.30]
9.1 Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation	3	1793	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.51, 1.30]
9.2 Late gestational age (20 weeks or more of gestation) at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
9.3 Unspecified or mixed gestational age at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
10 Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by anaemia status at the start of supplementation	3	1793	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.51, 1.30]
10.1 Anaemic at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
10.2 Non-anaemic at start of supplementation	1	97	Risk Ratio (M-H, Random, 95% CI)	2.5 [0.10, 59.88]

Europe PMC Funders Author Manuscripts

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
10.3 Unspecified or mixed anaemic status at start of supplementation	2	1696	Risk Ratio (M-H, Random, 95% CI)	0.79 [0.49, 1.27]
11 Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by dose of iron	3	1793	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.51, 1.30]
11.1 Low daily dose (30 mg elemental iron or less)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
11.2 Medium daily dose (31 to 59 mg elemental iron)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
11.3 Higher daily dose (60 mg elemental iron and above)	3	1793	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.51, 1.30]
12 Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by malarial status at the start of supplementation	3	1793	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.51, 1.30]
12.1 Malarial setting	1	1648	Risk Ratio (M-H, Random, 95% CI)	0.79 [0.49, 1.27]
12.2 Non-malarial setting	2	145	Risk Ratio (M-H, Random, 95% CI)	2.5 [0.10, 59.88]
13 Congenital anomalies (ALL)	1	1652	Risk Ratio (M-H, Random, 95% CI)	0.70 [0.35, 1.40]
14 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more) (ALL)	3	346	Risk Ratio (M-H, Random, 95% CI)	0.34 [0.21, 0.54]
15 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestation at the start of supplementation	3	346	Risk Ratio (M-H, Random, 95% CI)	0.34 [0.21, 0.54]
15.1 Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation	1	97	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
15.2 Late gestational age (20 weeks or more of gestation) at start of supplementation	1	66	Risk Ratio (M-H, Random, 95% CI)	0.37 [0.22, 0.62]
15.3 Unspecified or mixed gestational age at start of supplementation	1	183	Risk Ratio (M-H, Random, 95% CI)	0.24 [0.09, 0.68]
16 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation	3	346	Risk Ratio (M-H, Random, 95% CI)	0.34 [0.21, 0.54]
16.1 Anaemic at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
16.2 Non-anaemic at start of supplementation	2	280	Risk Ratio (M-H, Random, 95% CI)	0.24 [0.09, 0.68]
16.3 Unspecified or mixed anaemic status at start of supplementation	1	66	Risk Ratio (M-H, Random, 95% CI)	0.37 [0.22, 0.62]
17 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron	3	346	Risk Ratio (M-H, Random, 95% CI)	0.34 [0.21, 0.54]
17.1 Low daily dose (30 mg elemental iron or less)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
17.2 Medium daily dose (31 to 59 mg elemental iron)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
17.3 Higher daily dose (60 mg elemental iron and above)	3	346	Risk Ratio (M-H, Random, 95% CI)	0.34 [0.21, 0.54]
18 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting	3	346	Risk Ratio (M-H, Random, 95% CI)	0.34 [0.21, 0.54]
18.1 Malarial setting	1	66	Risk Ratio (M-H, Random, 95% CI)	0.37 [0.22, 0.62]
18.2 Non-malarial setting	2	280	Risk Ratio (M-H, Random, 95% CI)	0.24 [0.09, 0.68]
19 Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more) (ALL)	1	131	Risk Ratio (M-H, Random, 95% CI)	0.24 [0.06, 0.99]
20 Maternal iron deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicators at 37 weeks' gestation or more) (ALL)	1	131	Risk Ratio (M-H, Random, 95% CI)	0.43 [0.17, 1.09]

Europe PMC Funders Author Manuscripts

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
21 Maternal death (death while pregnant or within 42 days of termination of pregnancy) (ALL)	1	131	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
22 Side effects (any reported throughout the intervention period) (ALL)	1	456	Risk Ratio (M-H, Random, 95% CI)	44.32 [2.77, 709.09]
23 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L) (ALL)	4	506	Risk Ratio (M-H, Random, 95% CI)	0.12 [0.02, 0.63]
24 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by gestation at the start of supplementation	4	506	Risk Ratio (M-H, Random, 95% CI)	0.12 [0.02, 0.63]
24.1 Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation	3	456	Risk Ratio (M-H, Random, 95% CI)	0.11 [0.01, 0.83]
24.2 Late gestational age (20 weeks or more of gestation) at start of supplementation	1	50	Risk Ratio (M-H, Random, 95% CI)	0.14 [0.01, 2.63]
24.3 Unspecified or mixed gestational age at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
25 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by anaemia status at the start of supplementation	4	506	Risk Ratio (M-H, Random, 95% CI)	0.12 [0.02, 0.63]
25.1 Anaemic at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
25.2 Non-anaemic at start of supplementation	1	97	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
25.3 Unspecified or mixed anaemic status at start of supplementation	3	409	Risk Ratio (M-H, Random, 95% CI)	0.12 [0.02, 0.63]
26 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by dose of iron	4	506	Risk Ratio (M-H, Random, 95% CI)	0.12 [0.02, 0.63]
26.1 Low daily dose (30 mg elemental iron or less)	1	44	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
26.2 Medium daily dose (31 to 59 mg elemental iron)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
26.3 Higher daily dose (60 mg elemental iron and above)	3	462	Risk Ratio (M-H, Random, 95% CI)	0.12 [0.02, 0.63]
27 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by malarial status of setting	4	506	Risk Ratio (M-H, Random, 95% CI)	0.12 [0.02, 0.63]
27.1 Malarial setting	3	409	Risk Ratio (M-H, Random, 95% CI)	0.12 [0.02, 0.63]
27.2 Non-malarial setting	1	97	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
28 Maternal clinical malaria	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
29 Infection during pregnancy (including urinary tract infections) (ALL)	1	48	Risk Ratio (M-H, Random, 95% CI)	1.0 [0.15, 6.53]
30 Very low birthweight (less than 1500 g) (ALL)	1	48	Risk Ratio (M-H, Random, 95% CI)	5.0 [0.25, 98.96]
31 Very premature birth (less than 34 weeks' gestation) (ALL)	2	92	Risk Ratio (M-H, Random, 95% CI)	5.0 [0.25, 98.96]
32 Admission to special care unit (ALL)	1	48	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
33 Maternal anaemia at or near term (Hb less than 110 g/L at 34 weeks' gestation or more) (ALL)	3	346	Risk Ratio (M-H, Random, 95% CI)	0.34 [0.21, 0.54]
34 Maternal iron deficiency at or near term (as defined by trialists, based on any indicator of iron status at 34 weeks' gestation or more) (ALL)	1	131	Risk Ratio (M-H, Random, 95% CI)	0.24 [0.06, 0.99]
35 Maternal iron-deficiency anaemia at or near term (Hb less than 110 g/L and at least one additional laboratory indicators at 34 weeks' gestation or more) (ALL)	1	131	Risk Ratio (M-H, Random, 95% CI)	0.43 [0.17, 1.09]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
36 Maternal Hb concentration at or near term (in g/L, at 34 weeks' gestation or more) (ALL)	3	140	Mean Difference (IV, Random, 95% CI)	16.13 [12.74, 19.52]
37 Maternal Hb concentration within 6 wk postpartum (in g/L) (ALL)	2	459	Mean Difference (IV, Random, 95% CI)	10.07 [7.33, 12.81]
38 Maternal high haemoglobin concentrations during second or third trimester (Hb more than 130 g/L) (ALL)	2	446	Risk Ratio (M-H, Random, 95% CI)	1.78 [0.63, 5.04]
39 Maternal high haemoglobin concentrations at or near term (Hb more than 130 g/L at 34 weeks' gestation or more) (ALL)	2	314	Risk Ratio (M-H, Random, 95% CI)	4.37 [0.58, 32.71]
40 Moderate anaemia at postpartum (Hb more than 80 g/L and less than 110 g/L) (ALL)	3	491	Risk Ratio (M-H, Random, 95% CI)	0.33 [0.17, 0.65]
41 Maternal severe anaemia at or near term (Hb less than 70 g/L at 34 weeks' gestation or more) (ALL)	3	191	Risk Ratio (M-H, Random, 95% CI)	0.14 [0.01, 2.63]
42 Severe anaemia at postpartum (Hb less than 80 g/L) (ALL)	3	491	Risk Ratio (M-H, Random, 95% CI)	0.05 [0.00, 0.76]
43 Puerperal infection (ALL)	1	2863	Risk Ratio (M-H, Random, 95% CI)	0.55 [0.13, 2.28]
44 Antepartum haemorrhage (ALL)	2	145	Risk Ratio (M-H, Random, 95% CI)	1.25 [0.22, 7.12]
45 Postpartum haemorrhage (ALL)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
46 Placental abruption (ALL)	1	2863	Risk Ratio (M-H, Random, 95% CI)	8.19 [0.49, 138.16]
47 Pre-eclampsia (ALL)	1	48	Risk Ratio (M-H, Random, 95% CI)	3.0 [0.13, 70.16]

Comparison 3

Supplementation with iron alone versus no treatment/placebo

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Low birthweight (less than 2500 g) (ALL)	7	3830	Risk Ratio (M-H, Random, 95% CI)	0.71 [0.42, 1.19]
2 Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by gestational age at the start of supplementation	7	3830	Risk Ratio (M-H, Random, 95% CI)	0.71 [0.42, 1.19]
2.1 Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation	3	3055	Risk Ratio (M-H, Random, 95% CI)	0.53 [0.22, 1.23]
2.2 Late gestational age (20 weeks or more of gestation) at start of supplementation	3	665	Risk Ratio (M-H, Random, 95% CI)	1.05 [0.50, 2.19]
2.3 Unspecified or mixed gestational age at the start of supplementation	1	110	Risk Ratio (M-H, Random, 95% CI)	1.79 [0.17, 19.20]
3 Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by anaemia status at the start of supplementation	7	3830	Risk Ratio (M-H, Random, 95% CI)	0.71 [0.42, 1.19]
3.1 Anaemic at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
3.2 Non-anaemic at start of supplementation	6	3649	Risk Ratio (M-H, Random, 95% CI)	0.72 [0.39, 1.32]
3.3 Unspecified or mixed anaemic status at start of supplementation	1	181	Risk Ratio (M-H, Random, 95% CI)	0.57 [0.14, 2.31]
4 Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by dose of iron	7	3830	Risk Ratio (M-H, Random, 95% CI)	0.71 [0.42, 1.19]
4.1 Low daily dose (30 mg elemental iron or less)	3	697	Risk Ratio (M-H, Random, 95% CI)	0.59 [0.12, 2.96]
4.2 Medium daily dose (31 to 59 mg elemental iron)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
4.3 Higher daily dose (60 mg elemental iron and above)	4	3133	Risk Ratio (M-H, Random, 95% CI)	0.83 [0.56, 1.23]

Europe PMC Funders Author Manuscripts

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
5 Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by malarial status of setting	7	3830	Risk Ratio (M-H, Random, 95% CI)	0.71 [0.42, 1.19]
5.1 Malarial setting	2	329	Risk Ratio (M-H, Random, 95% CI)	0.52 [0.20, 1.35]
5.2 Non-malarial setting	5	3501	Risk Ratio (M-H, Random, 95% CI)	0.77 [0.38, 1.57]
6 Birthweight (g) (ALL)	9	3953	Mean Difference (IV, Random, 95% CI)	16.43 [−37.28, 70.14]
7 Birthweight (g): SUBGROUP ANALYSIS by gestational age at the start of supplementation	9	3953	Mean Difference (IV, Random, 95% CI)	16.43 [−37.28, 70.14]
7.1 Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation	5	3099	Mean Difference (IV, Random, 95% CI)	30.74 [−83.78, 145.25]
7.2 Late gestational age (20 weeks or more of gestation) at start of supplementation	4	854	Mean Difference (IV, Random, 95% CI)	−8.70 [−74.71, 57.31]
7.3 Unspecified or mixed gestational age at the start of supplementation	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
8 Birthweight (g): SUBGROUP ANALYSIS by anaemia status at the start of supplementation	9	3953	Mean Difference (IV, Random, 95% CI)	16.43 [−37.28, 70.14]
8.1 Anaemic at start of supplementation	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
8.2 Non-anaemic at start of supplementation	7	3583	Mean Difference (IV, Random, 95% CI)	22.44 [−54.15, 99.03]
8.3 Unspecified or mixed anaemic status at start of supplementation	2	370	Mean Difference (IV, Random, 95% CI)	0.90 [−86.32, 88.12]
9 Birthweight (g): SUBGROUP ANALYSIS by dose of iron	9	3953	Mean Difference (IV, Random, 95% CI)	15.73 [−33.92, 65.38]
9.1 Low daily dose (30 mg elemental iron or less)	4	785	Mean Difference (IV, Random, 95% CI)	46.83 [−76.57, 170.22]
9.2 Medium daily dose (31 to 59 mg elemental iron)	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
9.3 Higher daily dose (60 mg elemental iron and above)	6	3168	Mean Difference (IV, Random, 95% CI)	12.51 [−25.07, 50.10]
10 Birthweight (g): SUBGROUP ANALYSIS by malarial status of setting	9	3953	Mean Difference (IV, Random, 95% CI)	16.43 [−37.28, 70.14]
10.1 Malarial setting	2	345	Mean Difference (IV, Random, 95% CI)	33.74 [−61.16, 128.65]
10.2 Non-malarial setting	7	3608	Mean Difference (IV, Random, 95% CI)	10.18 [−65.06, 85.42]
11 Premature birth (less than 37 weeks of gestation) (ALL)	7	4407	Risk Ratio (M-H, Random, 95% CI)	0.77 [0.60, 1.00]
12 Premature birth (less 37 weeks of gestation): SUBGROUP ANALYSIS by gestational age at the start of supplementation	7	4407	Risk Ratio (M-H, Random, 95% CI)	0.77 [0.60, 1.00]
12.1 Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation	5	3930	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.61, 1.07]
12.2 Late gestational age (20 weeks or more of gestation) at start of supplementation	2	477	Risk Ratio (M-H, Random, 95% CI)	0.58 [0.29, 1.13]
12.3 Unspecified or mixed gestational age at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
13 Premature birth (less 37 weeks of gestation): SUBGROUP ANALYSIS by anaemia status at the start of supplementation	7	4407	Risk Ratio (M-H, Random, 95% CI)	0.77 [0.60, 1.00]
13.1 Anaemic at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
13.2 Non-anaemic at start of supplementation	6	3545	Risk Ratio (M-H, Random, 95% CI)	0.71 [0.53, 0.97]
13.3 Unspecified or mixed anaemic status at start of supplementation	1	862	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.58, 1.57]
14 Premature birth (less 37 weeks of gestation): SUBGROUP ANALYSIS by dose of iron	7	4407	Risk Ratio (M-H, Random, 95% CI)	0.77 [0.60, 1.00]

Europe PMC Funders Author Manuscripts

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
14.1 Low daily dose (30 mg elemental iron or less)	3	690	Risk Ratio (M-H, Random, 95% CI)	0.76 [0.47, 1.24]
14.2 Medium daily dose (31 to 59 mg elemental iron)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
14.3 Higher daily dose (60 mg elemental iron and above)	4	3717	Risk Ratio (M-H, Random, 95% CI)	0.78 [0.57, 1.05]
15 Premature birth (less 37 weeks of gestation): SUBGROUP ANALYSIS by malarial status of setting	7	4407	Risk Ratio (M-H, Random, 95% CI)	0.77 [0.60, 1.00]
15.1 Malarial setting	2	1010	Risk Ratio (M-H, Random, 95% CI)	0.87 [0.54, 1.39]
15.2 Non-malarial setting	5	3397	Risk Ratio (M-H, Random, 95% CI)	0.73 [0.54, 0.99]
16 Neonatal death (within 28 days after delivery) (ALL)	1	2694	Risk Ratio (M-H, Random, 95% CI)	1.32 [0.58, 3.00]
17 Congenital anomalies (ALL)	2	2402	Risk Ratio (M-H, Random, 95% CI)	0.86 [0.55, 1.35]
18 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more) (ALL)	14	2136	Risk Ratio (M-H, Random, 95% CI)	0.29 [0.19, 0.47]
19 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation	14	4693	Risk Ratio (M-H, Random, 95% CI)	0.26 [0.17, 0.40]
19.1 Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation	7	3243	Risk Ratio (M-H, Random, 95% CI)	0.24 [0.12, 0.50]
19.2 Late gestational age (20 weeks or more of gestation) at start of supplementation	6	1301	Risk Ratio (M-H, Random, 95% CI)	0.32 [0.20, 0.53]
19.3 Unspecified or mixed gestational age at start of supplementation	1	149	Risk Ratio (M-H, Random, 95% CI)	0.03 [0.00, 0.18]
20 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation	14	4630	Risk Ratio (M-H, Random, 95% CI)	0.26 [0.16, 0.41]
20.1 Anaemic at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
20.2 Non-anaemic at start of supplementation	9	3938	Risk Ratio (M-H, Random, 95% CI)	0.23 [0.13, 0.41]
20.3 Unspecified or mixed anaemic status at start of supplementation	5	692	Risk Ratio (M-H, Random, 95% CI)	0.34 [0.18, 0.64]
21 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron	14	4693	Risk Ratio (M-H, Random, 95% CI)	0.26 [0.17, 0.40]
21.1 Low daily dose (30 mg elemental iron or less)	3	590	Risk Ratio (M-H, Random, 95% CI)	0.49 [0.24, 1.03]
21.2 Medium daily dose (31 to 59 mg elemental iron)	1	69	Risk Ratio (M-H, Random, 95% CI)	0.21 [0.06, 0.73]
21.3 Higher daily dose (60 mg elemental iron and above)	10	4034	Risk Ratio (M-H, Random, 95% CI)	0.21 [0.12, 0.37]
22 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting	14	4630	Risk Ratio (M-H, Random, 95% CI)	0.26 [0.16, 0.41]
22.1 Malarial setting	2	267	Risk Ratio (M-H, Random, 95% CI)	0.58 [0.46, 0.72]
22.2 Non-malarial setting	12	4363	Risk Ratio (M-H, Random, 95% CI)	0.21 [0.12, 0.34]
23 Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more) (ALL)	7	1256	Risk Ratio (M-H, Random, 95% CI)	0.43 [0.27, 0.66]
24 Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation	7	1256	Risk Ratio (M-H, Random, 95% CI)	0.43 [0.27, 0.66]

Europe PMC Funders Author Manuscripts

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
24.1 Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation	4	653	Risk Ratio (M-H, Random, 95% CI)	0.45 [0.22, 0.93]
24.2 Late gestational age (20 weeks or more of gestation) at start of supplementation	3	603	Risk Ratio (M-H, Random, 95% CI)	0.36 [0.18, 0.72]
24.3 Unspecified or mixed gestational age at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
25 Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation	7	1256	Risk Ratio (M-H, Random, 95% CI)	0.43 [0.27, 0.66]
25.1 Anaemic at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
25.2 Non-anaemic at start of supplementation	5	1092	Risk Ratio (M-H, Random, 95% CI)	0.56 [0.39, 0.82]
25.3 Unspecified or mixed anaemic status at start of supplementation	2	164	Risk Ratio (M-H, Random, 95% CI)	0.14 [0.07, 0.29]
26 Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron	7	1256	Risk Ratio (M-H, Random, 95% CI)	0.43 [0.27, 0.66]
26.1 Low daily dose (30 mg elemental iron or less)	3	703	Risk Ratio (M-H, Random, 95% CI)	0.52 [0.34, 0.78]
26.2 Medium daily dose (31 to 59 mg elemental iron)	1	241	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.73, 1.17]
26.3 Higher daily dose (60 mg elemental iron and above)	3	312	Risk Ratio (M-H, Random, 95% CI)	0.21 [0.10, 0.41]
27 Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting	7	1256	Risk Ratio (M-H, Random, 95% CI)	0.43 [0.27, 0.66]
27.1 Malarial setting	2	192	Risk Ratio (M-H, Random, 95% CI)	0.28 [0.15, 0.53]
27.2 Non-malarial setting	5	1064	Risk Ratio (M-H, Random, 95% CI)	0.49 [0.30, 0.78]
28 Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicators at 37 weeks' gestation or more) (ALL)	6	1088	Risk Ratio (M-H, Random, 95% CI)	0.33 [0.16, 0.69]
29 Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicators at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation	6	1088	Risk Ratio (M-H, Random, 95% CI)	0.33 [0.16, 0.69]
29.1 Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation	4	660	Risk Ratio (M-H, Random, 95% CI)	0.39 [0.13, 1.11]
29.2 Late gestational age (20 weeks or more of gestation) at start of supplementation	2	428	Risk Ratio (M-H, Random, 95% CI)	0.25 [0.11, 0.58]
29.3 Unspecified or mixed gestational age at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
30 Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicators at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation	6	1088	Risk Ratio (M-H, Random, 95% CI)	0.33 [0.16, 0.69]
30.1 Anaemic at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
30.2 Non-anaemic at start of supplementation	5	968	Risk Ratio (M-H, Random, 95% CI)	0.39 [0.20, 0.74]
30.3 Unspecified or mixed anaemic status at start of supplementation	1	120	Risk Ratio (M-H, Random, 95% CI)	0.04 [0.00, 0.72]
31 Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicators at 37 weeks'	6	1088	Risk Ratio (M-H, Random, 95% CI)	0.33 [0.16, 0.69]

Europe PMC Funders Author Manuscripts

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
gestation or more): SUBGROUP ANALYSIS by dose of iron				
31.1 Daily low dose (60 mg elemental iron or less)	3	579	Risk Ratio (M-H, Random, 95% CI)	0.38 [0.13, 1.11]
31.2 Medium dose (31 to 59 mg elemental iron)	1	241	Risk Ratio (M-H, Random, 95% CI)	0.34 [0.16, 0.70]
31.3 High dose (60 mg elemental iron and above)	2	268	Risk Ratio (M-H, Random, 95% CI)	0.04 [0.00, 0.72]
32 Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicators at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting	6	1088	Risk Ratio (M-H, Random, 95% CI)	0.33 [0.16, 0.69]
32.1 Malarial setting	1	148	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
32.2 Non-malarial setting	5	940	Risk Ratio (M-H, Random, 95% CI)	0.33 [0.16, 0.69]
33 Maternal death (death while pregnant or within 42 days of termination of pregnancy) (ALL)	1	47	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
34 Side effects (any reported throughout the intervention period) (ALL)	10	4232	Risk Ratio (M-H, Random, 95% CI)	2.92 [1.10, 7.76]
35 Side effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by gestational age at the start of supplementation	10	4232	Risk Ratio (M-H, Random, 95% CI)	2.92 [1.10, 7.76]
35.1 Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation	4	2993	Risk Ratio (M-H, Random, 95% CI)	3.65 [0.40, 33.51]
35.2 Late gestational age (20 weeks or more of gestation) at start of supplementation	5	1034	Risk Ratio (M-H, Random, 95% CI)	1.42 [0.89, 2.28]
35.3 Unspecified or mixed gestational age at start of supplementation	1	205	Risk Ratio (M-H, Random, 95% CI)	62.79 [3.89, 1013.31]
36 Side effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by anaemia status at the start of supplementation	10	4232	Risk Ratio (M-H, Random, 95% CI)	2.92 [1.10, 7.76]
36.1 Anaemic at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
36.2 Non-anaemic at start of supplementation	6	3455	Risk Ratio (M-H, Random, 95% CI)	2.25 [0.57, 8.93]
36.3 Unspecified or mixed anaemic status at start of supplementation	4	777	Risk Ratio (M-H, Random, 95% CI)	5.11 [0.78, 33.60]
37 Side effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by dose of iron	10	4232	Risk Ratio (M-H, Random, 95% CI)	2.75 [1.10, 6.89]
37.1 Low daily dose (30 mg elemental iron or less)	4	785	Risk Ratio (M-H, Random, 95% CI)	1.07 [0.90, 1.26]
37.2 Medium daily dose (31 to 59 mg elemental iron)	2	225	Risk Ratio (M-H, Random, 95% CI)	2.00 [0.66, 6.02]
37.3 Higher daily dose (60 mg elemental iron and above)	6	3222	Risk Ratio (M-H, Random, 95% CI)	7.95 [1.38, 45.72]
38 Side effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by malarial status of setting	10	4232	Risk Ratio (M-H, Random, 95% CI)	2.92 [1.10, 7.76]
38.1 Malarial setting	1	205	Risk Ratio (M-H, Random, 95% CI)	62.79 [3.89, 1013.31]
38.2 Non-malarial setting	9	4027	Risk Ratio (M-H, Random, 95% CI)	2.35 [0.89, 6.24]
39 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L) (ALL)	7	1078	Risk Ratio (M-H, Random, 95% CI)	0.75 [0.02, 29.10]
40 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by gestational age at the start of supplementation	7	1078	Risk Ratio (M-H, Random, 95% CI)	0.75 [0.02, 29.10]

Europe PMC Funders Author Manuscripts

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
40.1 Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation	3	416	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
40.2 Late gestational age (20 weeks or more of gestation) at start of supplementation	3	513	Risk Ratio (M-H, Random, 95% CI)	0.75 [0.02, 29.10]
40.3 Unspecified or mixed gestational age at start of supplementation	1	149	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
41 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by anaemia status age at the start of supplementation	7	1078	Risk Ratio (M-H, Random, 95% CI)	0.75 [0.02, 29.10]
41.1 Anaemic at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
41.2 Non-anaemic at start of supplementation	5	816	Risk Ratio (M-H, Random, 95% CI)	4.98 [0.24, 103.01]
41.3 Unspecified or mixed anaemic status at start of supplementation	2	262	Risk Ratio (M-H, Random, 95% CI)	0.12 [0.01, 2.21]
42 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by dose of iron	7	1078	Risk Ratio (M-H, Random, 95% CI)	0.75 [0.02, 29.10]
42.1 Low daily dose (30 mg elemental iron or less)	3	654	Risk Ratio (M-H, Random, 95% CI)	4.98 [0.24, 103.01]
42.2 Medium daily dose (31 to 59 mg elemental iron)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
42.3 Higher daily dose (60 mg elemental iron and above)	4	424	Risk Ratio (M-H, Random, 95% CI)	0.12 [0.01, 2.21]
43 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by malarial status of setting	7	1078	Risk Ratio (M-H, Random, 95% CI)	0.75 [0.02, 29.10]
43.1 Malarial setting	1	55	Risk Ratio (M-H, Random, 95% CI)	0.12 [0.01, 2.21]
43.2 Non-malarial setting	6	1023	Risk Ratio (M-H, Random, 95% CI)	4.98 [0.24, 103.01]
44 Maternal clinical malaria	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
45 Infection during pregnancy (including urinary tract infections) (ALL)	1	2694	Risk Ratio (M-H, Random, 95% CI)	1.16 [0.82, 1.65]
46 Very low birthweight (less than 1500 g) (ALL)	3	697	Risk Ratio (M-H, Random, 95% CI)	0.55 [0.03, 9.07]
47 Very premature birth (less than 34 weeks' gestation) (ALL)	3	690	Risk Ratio (M-H, Random, 95% CI)	0.32 [0.10, 1.09]
48 Infant Hb concentration in the first 6 months (in g/L, counting the last reported measure after birth within this period) (ALL)	2	533	Mean Difference (IV, Random, 95% CI)	−1.25 [−8.10, 5.59]
49 Infant serum ferritin concentration in the first 6 months (in μg/L, counting the last reported measure after birth within this period) (ALL)	1	197	Mean Difference (IV, Random, 95% CI)	11.0 [4.37, 17.63]
50 Admission to special care unit (ALL)	2	2805	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.73, 1.23]
51 Maternal anaemia at or near term (Hb less than 110 g/L at 34 weeks' gestation or more) (ALL)	14	4390	Risk Ratio (M-H, Random, 95% CI)	0.29 [0.19, 0.45]
52 Maternal iron deficiency at or near term (as defined by trialists, based on any indicator of iron status at 34 weeks' gestation or more) (ALL)	7	1256	Risk Ratio (M-H, Random, 95% CI)	0.43 [0.27, 0.66]
53 Maternal iron-deficiency anaemia at or near term (Hb less than 110 g/L and at least one additional laboratory indicators at 34 weeks' gestation or more) (ALL)	6	1088	Risk Ratio (M-H, Random, 95% CI)	0.33 [0.16, 0.69]
54 Maternal Hb concentration at or near term (in g/L, at 34 weeks' gestation or more) (ALL)	16	1851	Mean Difference (IV, Random, 95% CI)	8.95 [6.37, 11.53]
55 Maternal Hb concentration within 6 wk postpartum (in g/L) (ALL)	6	659	Mean Difference (IV, Random, 95% CI)	7.26 [4.78, 9.74]

Europe PMC Funders Author Manuscripts

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
56 Maternal high haemoglobin concentrations during second or third trimester (Hb more than 130 g/L) (ALL)	8	3840	Risk Ratio (M-H, Random, 95% CI)	1.81 [1.21, 2.71]
57 Maternal high haemoglobin concentrations at or near term (Hb more than 130 g/L at 34 weeks' gestation or more) (ALL)	8	3883	Risk Ratio (M-H, Random, 95% CI)	3.67 [2.23, 6.04]
58 Moderate anaemia at postpartum (Hb more than 80 g/L and less than 110 g/L) (ALL)	3	453	Risk Ratio (M-H, Random, 95% CI)	0.46 [0.02, 13.91]
59 Maternal severe anaemia at or near term (Hb less than 70 g/L at 34 weeks' gestation or more) (ALL)	7	1046	Risk Ratio (M-H, Random, 95% CI)	0.74 [0.02, 27.81]
60 Severe anaemia at postpartum (Hb less than 80 g/L) (ALL)	7	953	Risk Ratio (M-H, Random, 95% CI)	0.02 [0.00, 0.33]
61 Puerperal infection (ALL)	2	2292	Risk Ratio (M-H, Random, 95% CI)	0.65 [0.41, 1.03]
62 Antepartum haemorrhage (ALL)	1	430	Risk Ratio (M-H, Random, 95% CI)	2.97 [0.12, 72.56]
63 Postpartum haemorrhage (ALL)	3	761	Risk Ratio (M-H, Random, 95% CI)	0.82 [0.51, 1.34]
64 Transfusion provided (ALL)	2	2726	Risk Ratio (M-H, Random, 95% CI)	0.59 [0.37, 0.94]
65 Diarrhoea (ALL)	1	173	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.09, 10.61]
66 Constipation (ALL)	2	580	Risk Ratio (M-H, Random, 95% CI)	0.88 [0.18, 4.40]
67 Nausea (ALL)	3	650	Risk Ratio (M-H, Random, 95% CI)	2.38 [0.49, 11.52]
68 Heartburn (ALL)	1	408	Risk Ratio (M-H, Random, 95% CI)	1.0 [0.82, 1.22]
69 Vomiting (ALL)	2	477	Risk Ratio (M-H, Random, 95% CI)	0.88 [0.38, 2.07]
70 Maternal wellbeing/satisfaction (ALL)	2	2604	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.91, 1.09]
71 Placental abruption (ALL)	1	1442	Risk Ratio (M-H, Random, 95% CI)	2.88 [0.12, 70.53]
72 Premature rupture of membranes (ALL)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
73 Pre-eclampsia (ALL)	1	47	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.06, 14.43]

Comparison 4

Supplementation with iron+folic acid versus no treatment/placebo

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Low birthweight (less than 2500 g) (ALL)	2	1311	Risk Ratio (M-H, Random, 95% CI)	1.07 [0.31, 3.74]
2 Birthweight (ALL)	2	1365	Mean Difference (IV, Random, 95% CI)	57.73 [7.66, 107.79]
3 Premature birth (less than 37 weeks of gestation) (ALL)	3	1497	Risk Ratio (M-H, Random, 95% CI)	1.55 [0.40, 6.00]
4 Premature birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by gestational age at the start of supplementation	3	1410	Risk Ratio (M-H, Random, 95% CI)	1.55 [0.40, 6.00]
4.1 Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation	2	1366	Risk Ratio (M-H, Random, 95% CI)	1.55 [0.40, 6.00]
4.2 Late gestational age (20 weeks or more of gestation) at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
4.3 Unspecified or mixed gestational age at start of supplementation	1	44	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]

Europe PMC Funders Author Manuscripts

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
5 Premature birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by anaemia status at the start of supplementation	3	1497	Risk Ratio (M-H, Random, 95% CI)	1.55 [0.40, 6.00]
5.1 Anaemic at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
5.2 Non-anaemic at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
5.3 Unspecified or mixed anaemic status at start of supplementation	3	1497	Risk Ratio (M-H, Random, 95% CI)	1.55 [0.40, 6.00]
6 Premature birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by dose of iron	3	1497	Risk Ratio (M-H, Random, 95% CI)	1.55 [0.40, 6.00]
6.1 Low daily dose (30 mg elemental iron or less)	1	131	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
6.2 Medium daily dose (31 to 59 mg elemental iron)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
6.3 Higher daily dose (60 mg elemental iron and above)	2	1366	Risk Ratio (M-H, Random, 95% CI)	1.55 [0.40, 6.00]
7 Premature birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by malarial status of setting	3	1497	Risk Ratio (M-H, Random, 95% CI)	1.55 [0.40, 6.00]
7.1 Malarial setting	2	1449	Risk Ratio (M-H, Random, 95% CI)	1.13 [0.92, 1.39]
7.2 Non-malarial setting	1	48	Risk Ratio (M-H, Random, 95% CI)	7.00 [0.38, 128.61]
8 Neonatal death (within 28 days after delivery) (ALL)	3	1793	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.51, 1.30]
9 Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by gestational age at start of supplementation	3	1793	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.51, 1.30]
9.1 Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation	3	1793	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.51, 1.30]
9.2 Late gestational age (20 weeks or more of gestation) at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
9.3 Unspecified or mixed gestational age at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
10 Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by anaemia status at start of supplementation	3	1793	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.51, 1.30]
10.1 Anaemic at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
10.2 Non-anaemic at start of supplementation	1	97	Risk Ratio (M-H, Random, 95% CI)	2.5 [0.10, 59.88]
10.3 Unspecified or mixed anaemic status at start of supplementation	2	1696	Risk Ratio (M-H, Random, 95% CI)	0.79 [0.49, 1.27]
11 Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by dose of iron	3	1793	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.51, 1.30]
11.1 Low daily dose (30 mg elemental iron or less)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
11.2 Medium daily dose (31 to 59 mg elemental iron)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
11.3 Higher daily dose (60 mg elemental iron and above)	3	1793	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.51, 1.30]
12 Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by malarial status of setting	3	1793	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.51, 1.30]
12.1 Malarial setting	1	1648	Risk Ratio (M-H, Random, 95% CI)	0.79 [0.49, 1.27]
12.2 Non-malarial setting	2	145	Risk Ratio (M-H, Random, 95% CI)	2.5 [0.10, 59.88]
13 Congenital anomalies (ALL)	1	1652	Risk Ratio (M-H, Random, 95% CI)	0.70 [0.35, 1.40]
14 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more) (ALL)	3	346	Risk Ratio (M-H, Random, 95% CI)	0.34 [0.21, 0.54]

Europe PMC Funders Author Manuscripts

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
15 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation	3	346	Risk Ratio (M-H, Random, 95% CI)	0.34 [0.21, 0.54]
15.1 Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation	1	97	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
15.2 Late gestational age (20 weeks or more of gestation) at start of supplementation	2	249	Risk Ratio (M-H, Random, 95% CI)	0.34 [0.21, 0.54]
15.3 Unspecified or mixed gestational age at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
16 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation	3	346	Risk Ratio (M-H, Random, 95% CI)	0.34 [0.21, 0.54]
16.1 Anaemic at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
16.2 Non-anaemic at start of supplementation	2	280	Risk Ratio (M-H, Random, 95% CI)	0.24 [0.09, 0.68]
16.3 Unspecified or mixed anaemic status at start of supplementation	1	66	Risk Ratio (M-H, Random, 95% CI)	0.37 [0.22, 0.62]
17 Maternal anaemia at term (Hb less than 110 g/Lat 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron	3	346	Risk Ratio (M-H, Random, 95% CI)	0.34 [0.21, 0.54]
17.1 Low daily dose (30 mg elemental iron or less)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
17.2 Medium daily dose (31 to 59 mg elemental iron)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
17.3 Higher daily dose (60 mg elemental iron and above)	3	346	Risk Ratio (M-H, Random, 95% CI)	0.34 [0.21, 0.54]
18 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting	3	346	Risk Ratio (M-H, Random, 95% CI)	0.34 [0.21, 0.54]
18.1 Malarial setting	1	66	Risk Ratio (M-H, Random, 95% CI)	0.37 [0.22, 0.62]
18.2 Non-malarial setting	2	280	Risk Ratio (M-H, Random, 95% CI)	0.24 [0.09, 0.68]
19 Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more) (ALL)	1	131	Risk Ratio (M-H, Random, 95% CI)	0.24 [0.06, 0.99]
20 Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicators at 37 weeks' gestation or more) (ALL)	1	131	Risk Ratio (M-H, Random, 95% CI)	0.43 [0.17, 1.09]
21 Maternal death (death while pregnant or within 42 days of termination of pregnancy) (ALL)	1	131	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
22 Side effects (any reported throughout the intervention period) (ALL)	1	456	Risk Ratio (M-H, Random, 95% CI)	44.32 [2.77, 709.09]
23 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L) (ALL)	4	506	Risk Ratio (M-H, Random, 95% CI)	0.12 [0.02, 0.63]
24 Maternal clinical malaria	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
25 Infection during pregnancy (including urinary tract infections) (ALL)	1	48	Risk Ratio (M-H, Random, 95% CI)	1.0 [0.15, 6.53]
26 Very low birthweight (less than 1500 g) (ALL)	1	48	Risk Ratio (M-H, Random, 95% CI)	5.0 [0.25, 98.96]
27 Very premature birth (less than 34 weeks' gestation) (ALL)	2	92	Risk Ratio (M-H, Random, 95% CI)	5.0 [0.25, 98.96]
28 Infant Hb concentration in the first 6 months (in g/L, counting the last reported measure after birth within this period) (ALL)	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
29 Infant serum ferritin concentration in the first 6 months (in μg/L, counting the last reported measure after birth within this period) (ALL)	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]

Europe PMC Funders Author Manuscripts

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
30 Admission to special care unit (ALL)	1	48	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
31 Maternal anaemia at or near term (Hb less than 110 g/L at 34 weeks' gestation or more) (ALL)	3	346	Risk Ratio (M-H, Random, 95% CI)	0.34 [0.21, 0.54]
32 Maternal iron deficiency at or near term (as defined by trialists, based on any indicator of iron status at 34 weeks' gestation or more) (ALL)	1	131	Risk Ratio (M-H, Random, 95% CI)	0.24 [0.06, 0.99]
33 Maternal iron-deficiency anaemia at or near term (Hb less than 110 g/L and at least one additional laboratory indicators at 34 weeks' gestation or more) (ALL)	1	131	Risk Ratio (M-H, Random, 95% CI)	0.43 [0.17, 1.09]
34 Maternal Hb concentration at term or near term (in g/L, at 34 weeks' gestation or more) (ALL)	3	140	Mean Difference (IV, Random, 95% CI)	16.13 [12.74, 19.52]
35 Maternal Hb concentration within 6 wk postpartum (g/L) (ALL)	2	459	Mean Difference (IV, Random, 95% CI)	10.07 [7.33, 12.81]
36 Maternal high haemoglobin concentrations during second or third trimester (Hb more than 130 g/L) (ALL)	2	446	Risk Ratio (M-H, Random, 95% CI)	1.78 [0.63, 5.04]
37 Maternal high haemoglobin concentrations at or near term (Hb more than 130 g/L at 34 weeks' gestation or more) (ALL)	2	314	Risk Ratio (M-H, Random, 95% CI)	4.37 [0.58, 32.71]
38 Moderate anaemia at postpartum (Hb more than 80 g/L and less than 110 g/L) (ALL)	2	458	Risk Ratio (M-H, Random, 95% CI)	0.34 [0.17, 0.69]
39 Maternal severe anaemia at term or near (Hb less than 70 g/L at 34 weeks' gestation or more) (ALL)	3	191	Risk Ratio (M-H, Random, 95% CI)	0.14 [0.01, 2.63]
40 Severe anaemia at postpartum (Hb less than 80 g/L) (ALL)	3	491	Risk Ratio (M-H, Random, 95% CI)	0.05 [0.00, 0.76]
41 Puerperal infection (ALL)	1	2863	Risk Ratio (M-H, Random, 95% CI)	0.55 [0.13, 2.28]
42 Antepartum haemorrhage (ALL)	2	145	Risk Ratio (M-H, Random, 95% CI)	1.25 [0.22, 7.12]
43 Postpartum haemorrhage (ALL)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
44 Placental abruption (ALL)	1	2863	Risk Ratio (M-H, Random, 95% CI)	8.19 [0.49, 138.16]
45 Pre-eclampsia (ALL)	1	48	Risk Ratio (M-H, Random, 95% CI)	3.0 [0.13, 70.16]

Comparison 5

Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Low birthweight (less than 2500 g) (ALL)	3	4316	Risk Ratio (M-H, Random, 95% CI)	0.84 [0.73, 0.95]
2 Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by gestational age at the start of supplementation	3	4316	Risk Ratio (M-H, Random, 95% CI)	0.84 [0.73, 0.95]
2.1 Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation	2	1990	Risk Ratio (M-H, Random, 95% CI)	0.83 [0.73, 0.96]
2.2 Late gestational age (20 weeks or more of gestation) at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
2.3 Unspecified or mixed gestational age at the start of supplementation	1	2326	Risk Ratio (M-H, Random, 95% CI)	0.85 [0.59, 1.22]
3 Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by anaemia status at the start of supplementation	3	4316	Risk Ratio (M-H, Random, 95% CI)	0.84 [0.73, 0.95]
3.1 Anaemic at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]

Europe PMC Funders Author Manuscripts

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
3.2 Non-anaemic at start of supplementation	1	727	Risk Ratio (M-H, Random, 95% CI)	1.21 [0.57, 2.54]
3.3 Unspecified or mixed anaemia status	2	3589	Risk Ratio (M-H, Random, 95% CI)	0.83 [0.72, 0.94]
4 Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by dose of iron	3	4316	Risk Ratio (M-H, Random, 95% CI)	0.84 [0.73, 0.95]
4.1 Low daily dose (30 mg elemental iron or less)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
4.2 Medium daily dose (31 to 59 mg elemental iron)	1	727	Risk Ratio (M-H, Random, 95% CI)	1.21 [0.57, 2.54]
4.3 Higher daily dose (60 mg elemental iron and above)	2	3589	Risk Ratio (M-H, Random, 95% CI)	0.83 [0.72, 0.94]
5 Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by malarial status of setting	3	4316	Risk Ratio (M-H, Random, 95% CI)	0.84 [0.73, 0.95]
5.1 Malarial setting	3	4316	Risk Ratio (M-H, Random, 95% CI)	0.84 [0.73, 0.95]
5.2 Non-malarial setting	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
6 Birthweight (g) (ALL)	3	4316	Mean Difference (IV, Random, 95% CI)	32.23 [0.86, 63.60]
7 Birthweight (g): SUBGROUP ANALYSIS by gestational age at the start of supplementation	3	4316	Mean Difference (IV, Random, 95% CI)	32.23 [0.86, 63.60]
7.1 Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation	2	1990	Mean Difference (IV, Random, 95% CI)	41.19 [−12.23, 94.60]
7.2 Late gestational age (20 weeks or more of gestation) at start of supplementation	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
7.3 Unspecified or mixed gestational age at the start of supplementation	1	2326	Mean Difference (IV, Random, 95% CI)	20.20 [−15.13, 55.53]
8 Birthweight (g): SUBGROUP ANALYSIS by anaemia status at the start of supplementation	3	4316	Mean Difference (IV, Random, 95% CI)	32.23 [0.86, 63.60]
8.1 Anaemic at start of supplementation	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
8.2 Non-anaemic at start of supplementation	1	727	Mean Difference (IV, Random, 95% CI)	10.0 [−51.92, 71.92]
8.3 Unspecified or mixed anaemic status at start of supplementation	2	3589	Mean Difference (IV, Random, 95% CI)	39.61 [−3.90, 83.13]
9 Birthweight (g): SUBGROUP ANALYSIS by dose of iron	3	4316	Mean Difference (IV, Random, 95% CI)	32.23 [0.86, 63.60]
9.1 Low daily dose (30 mg elemental iron or less)	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
9.2 Medium daily dose (31 to 59 mg elemental iron)	1	727	Mean Difference (IV, Random, 95% CI)	10.0 [−51.92, 71.92]
9.3 Higher daily dose (60 mg elemental iron and above)	2	3589	Mean Difference (IV, Random, 95% CI)	39.61 [−3.90, 83.13]
10 Birthweight (g): SUBGROUP ANALYSIS by malarial status of setting	3	4316	Mean Difference (IV, Random, 95% CI)	32.23 [0.86, 63.60]
10.1 Malarial setting	3	4316	Mean Difference (IV, Random, 95% CI)	32.23 [0.86, 63.60]
10.2 Non-malarial setting	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
11 Premature birth (less than 37 weeks of gestation) (ALL)	3	4314	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.78, 1.20]
12 Premature birth (less 37 weeks of gestation): SUBGROUP ANALYSIS by gestational age at the start of supplementation	3	4314	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.78, 1.20]
12.1 Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation	2	1988	Risk Ratio (M-H, Random, 95% CI)	1.06 [0.87, 1.29]
12.2 Late gestational age (20 weeks or more of gestation) at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]

Europe PMC Funders Author Manuscripts

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
12.3 Unspecified or mixed gestational age at the start of supplementation	1	2326	Risk Ratio (M-H, Random, 95% CI)	0.79 [0.57, 1.09]
13 Premature birth (less 37 weeks of gestation): SUBGROUP ANALYSIS by anaemia status at the start of supplementation	3	4314	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.78, 1.20]
13.1 Anaemic at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
13.2 Non-anaemic at start of supplementation	1	727	Risk Ratio (M-H, Random, 95% CI)	1.26 [0.62, 2.56]
13.3 Unspecified or mixed anaemic status at start of supplementation	2	3587	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.71, 1.22]
14 Premature birth (less 37 weeks of gestation): SUBGROUP ANALYSIS by dose of iron	3	4314	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.78, 1.20]
14.1 Low daily dose (30 mg elemental iron or less)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
14.2 Medium daily dose (31 to 59 mg elemental iron)	1	727	Risk Ratio (M-H, Random, 95% CI)	1.26 [0.62, 2.56]
14.3 Higher daily dose (60 mg elemental iron and above)	2	3587	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.71, 1.22]
15 Premature birth (less 37 weeks of gestation): SUBGROUP ANALYSIS by malarial status of setting	3	4314	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.78, 1.20]
15.1 Malarial setting	3	4314	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.78, 1.20]
15.2 Non-malarial setting	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
16 Neonatal death (within 28 days after delivery) (ALL)	3	4771	Risk Ratio (M-H, Random, 95% CI)	0.85 [0.63, 1.15]
17 Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by gestational age at the start of supplementation	3	4771	Risk Ratio (M-H, Random, 95% CI)	0.85 [0.63, 1.15]
17.1 Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation	2	2276	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.57, 1.49]
17.2 Late gestational age (20 weeks or more of gestation) at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
17.3 Unspecified or mixed gestational age at the start of supplementation	1	2495	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.56, 1.19]
18 Neonatal death (within 28 days after delivery) : SUBGROUP ANALYSIS by anaemia status at the start of supplementation	3	4771	Risk Ratio (M-H, Random, 95% CI)	0.85 [0.63, 1.15]
18.1 Anaemic at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
18.2 Non-anaemic at start of supplementation	1	727	Risk Ratio (M-H, Random, 95% CI)	0.48 [0.12, 1.91]
18.3 Unspecified or mixed anaemic status at start of supplementation	2	4044	Risk Ratio (M-H, Random, 95% CI)	0.88 [0.65, 1.19]
19 Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by dose of iron	3	4771	Risk Ratio (M-H, Random, 95% CI)	0.85 [0.63, 1.15]
19.1 Low daily dose (30 mg elemental iron or less)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
19.2 Medium daily dose (31 to 59 mg elemental iron)	1	727	Risk Ratio (M-H, Random, 95% CI)	0.48 [0.12, 1.91]
19.3 Higher daily dose (60 mg elemental iron and above)	2	4044	Risk Ratio (M-H, Random, 95% CI)	0.88 [0.65, 1.19]
20 Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by malarial status of setting	3	4771	Risk Ratio (M-H, Random, 95% CI)	0.85 [0.63, 1.15]
20.1 Malarial setting	3	4771	Risk Ratio (M-H, Random, 95% CI)	0.85 [0.63, 1.15]
20.2 Non-malarial setting	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
21 Congenital anomalies (ALL)	1	1652	Risk Ratio (M-H, Random, 95% CI)	0.70 [0.35, 1.40]

Europe PMC Funders Author Manuscripts

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
22 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more) (ALL)	2	303	Risk Ratio (M-H, Random, 95% CI)	0.34 [0.21, 0.55]
23 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation	2	303	Risk Ratio (M-H, Random, 95% CI)	0.34 [0.21, 0.55]
23.1 Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
23.2 Late gestational age (20 weeks or more of gestation) at start of supplementation	2	303	Risk Ratio (M-H, Random, 95% CI)	0.34 [0.21, 0.55]
23.3 Unspecified or mixed gestational age at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
24 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation	2	303	Risk Ratio (M-H, Random, 95% CI)	0.34 [0.21, 0.55]
24.1 Anaemic at start of supplementation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
24.2 Non-anaemic at start of supplementation	1	240	Risk Ratio (M-H, Random, 95% CI)	0.24 [0.09, 0.61]
24.3 Unspecified or mixed anaemic status at start of supplementation	1	63	Risk Ratio (M-H, Random, 95% CI)	0.39 [0.23, 0.67]
25 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron	2	303	Risk Ratio (M-H, Random, 95% CI)	0.34 [0.21, 0.55]
25.1 Low daily dose (30 mg elemental iron or less)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
25.2 Medium daily dose (31 to 59 mg elemental iron)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
25.3 Higher daily dose (60 mg elemental iron and above)	2	303	Risk Ratio (M-H, Random, 95% CI)	0.34 [0.21, 0.55]
26 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting	2	303	Risk Ratio (M-H, Random, 95% CI)	0.34 [0.21, 0.55]
26.1 Malarial setting	1	63	Risk Ratio (M-H, Random, 95% CI)	0.39 [0.23, 0.67]
26.2 Non-malarial setting	1	240	Risk Ratio (M-H, Random, 95% CI)	0.24 [0.09, 0.61]
27 Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more) (ALL)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
28 Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicators at 37 weeks' gestation or more) (ALL)	1	727	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
29 Maternal death (death while pregnant or within 42 days of termination of pregnancy) (ALL)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
30 Side effects (any reported throughout the intervention period) (ALL)	1	727	Risk Ratio (M-H, Random, 95% CI)	1.10 [0.55, 2.23]
31 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L) (ALL)	3	1047	Risk Ratio (M-H, Random, 95% CI)	0.06 [0.01, 0.47]
32 Maternal clinical malaria	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
33 Infection during pregnancy (including urinary tract infections) (ALL)	1	727	Risk Ratio (M-H, Random, 95% CI)	1.21 [0.33, 4.46]
34 Very low birthweight (less than 1500 g) (ALL)	2	1990	Risk Ratio (M-H, Random, 95% CI)	0.76 [0.28, 2.01]
35 Very premature birth (less than 34 weeks' gestation) (ALL)	2	3053	Risk Ratio (M-H, Random, 95% CI)	0.58 [0.30, 1.12]
36 Infant Hb concentration in the first 6 months (in g/L, counting the last reported measure after birth within this period) (ALL)	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
37 Infant serum ferritin concentration in the first 6 months (in μg/L, counting the last	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]

Europe PMC Funders Author Manuscripts

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
reported measure after birth within this period) (ALL)				
38 Admission to special care unit (ALL)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
39 Maternal anaemia at or near term (Hb less than 110 g/L at 34 weeks' gestation or more) (ALL)	2	303	Risk Ratio (M-H, Random, 95% CI)	0.34 [0.21, 0.55]
40 Maternal iron deficiency at or near term (as defined by trialists, based on any indicator of iron status at 34 weeks' gestation or more) (ALL)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
41 Maternal iron-deficiency anaemia at or near term (Hb less than 110 g/L and at least one additional laboratory indicators at 34 weeks' gestation or more) (ALL)	1	727	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
42 Maternal Hb concentration at or near term (in g/L at 34 weeks' gestation or more) (ALL)	2	771	Mean Difference (IV, Random, 95% CI)	12.44 [0.95, 23.93]
43 Maternal Hb concentration within 6 wk postpartum (in g/L) (ALL)	1	297	Mean Difference (IV, Random, 95% CI)	9.20 [5.78, 12.62]
44 Maternal high haemoglobin concentrations during second or third trimester (Hb more than 130 g/L) (ALL)	2	1042	Risk Ratio (M-H, Random, 95% CI)	4.33 [2.26, 8.30]
45 Maternal high haemoglobin concentrations at or near term (Hb more than 130 g/L at 34 weeks' gestation or more) (ALL)	2	967	Risk Ratio (M-H, Random, 95% CI)	1.87 [0.32, 10.84]
46 Moderate anaemia at postpartum (Hb more than 80 g/L and less than 110 g/L) (ALL)	1	353	Risk Ratio (M-H, Random, 95% CI)	0.38 [0.18, 0.81]
47 Maternal severe anaemia at or near term (Hb less than 70 g/L at 34 weeks' gestation or more) (ALL)	2	773	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
48 Severe anaemia at postpartum (Hb less than 80 g/L) (ALL)	2	386	Risk Ratio (M-H, Random, 95% CI)	0.08 [0.00, 1.33]
49 Puerperal infection (ALL)	1	727	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.20, 4.75]
50 Antepartum haemorrhage (ALL)	1	727	Risk Ratio (M-H, Random, 95% CI)	1.35 [0.43, 4.22]
51 Postpartum haemorrhage (ALL)	1	727	Risk Ratio (M-H, Random, 95% CI)	3.38 [0.71, 16.15]
52 Transfusion provided (ALL)	1	727	Risk Ratio (M-H, Random, 95% CI)	2.89 [0.12, 70.83]
53 Diarrhoea (ALL)	1	727	Risk Ratio (M-H, Random, 95% CI)	0.55 [0.16, 1.87]
54 Constipation (ALL)	1	727	Risk Ratio (M-H, Random, 95% CI)	1.10 [0.55, 2.23]
55 Nausea (ALL)	1	727	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.47, 1.99]
56 Heartburn (ALL)	1	727	Risk Ratio (M-H, Random, 95% CI)	1.65 [0.66, 4.15]
57 Vomiting (ALL)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
58 Maternal wellbeing/satisfaction (ALL)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
59 Placental abruption (ALL)	1	727	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.24, 3.83]
60 Premature rupture of membranes (ALL)	1	727	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.74, 1.34]
61 Pre-eclampsia (ALL)	1	727	Risk Ratio (M-H, Random, 95% CI)	3.22 [0.89, 11.59]

Europe PMC Funders Author Manuscripts

Comparison 6

Supplementation with iron+other vitamins and minerals supplementation versus same other vitamins and minerals (without iron) supplementation

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Low birthweight (less than 2500 g) (ALL)	1	334	Risk Ratio (M-H, Random, 95% CI)	0.51 [0.22, 1.15]
2 Birthweight (g) (ALL)	2	1116	Mean Difference (IV, Random, 95% CI)	55.70 [3.42, 107.97]
3 Premature birth (less than 37 weeks of gestation) (ALL)	2	1127	Risk Ratio (M-H, Random, 95% CI)	0.66 [0.41, 1.04]
4 Neonatal death (within 28 days after delivery) (ALL)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
5 Congenital anomalies (ALL)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
6 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more) (ALL)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
7 Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more) (ALL)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
8 Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicators at 37 weeks' gestation or more) (ALL)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
9 Maternal death (death while pregnant or within 42 days of termination of pregnancy) (ALL)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
10 Side effects (any reported throughout the intervention period) (ALL)	1	188	Risk Ratio (M-H, Random, 95% CI)	0.77 [0.55, 1.07]
11 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L) (ALL)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
12 Maternal clinical malaria	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
13 Infection during pregnancy (including urinary tract infections) (ALL)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
14 Very low birthweight (less than 1500 g) (ALL)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
15 Very premature birth (less than 34 weeks' gestation) (ALL)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
16 Infant Hb concentration in the first 6 months (in g/L, counting the last reported measure after birth within this period) (ALL)	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
17 Infant serum ferritin concentration in the first 6 months (in μg/L, counting the last reported measure after birth within this period) (ALL)	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
18 Admission to special care unit (ALL)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
19 Maternal anaemia at or near term (Hb less than 110 g/L at 34 weeks' gestation or more) (ALL)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
20 Maternal iron deficiency at or near term (as defined by trialists, based on any indicator of iron status at 34 weeks' gestation or more) (ALL)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
21 Maternal iron-deficiency anaemia at or near term (Hb less than 110 g/L and at least one additional laboratory indicators at 34 weeks' gestation or more) (ALL)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
22 Maternal Hb concentration at or near term (in g/L at 34 weeks' gestation or more) (ALL)	2	809	Mean Difference (IV, Random, 95% CI)	10.85 [7.29, 14.42]
23 Maternal Hb concentration within 6 wk postpartum (in g/L) (ALL)	1	27	Mean Difference (IV, Random, 95% CI)	14.0 [3.56, 24.44]
24 Maternal high haemoglobin concentrations during second or third trimester (Hb more than 130 g/L) (ALL)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]

Europe PMC Funders Author Manuscripts

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
25 Maternal high haemoglobin concentrations at or near term (Hb more than 130 g/L at 34 weeks' gestation or more) (ALL)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
26 Moderate anaemia at postpartum (Hb more than 80 g/L and less than 110 g/L) (ALL)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
27 Maternal severe anaemia at or near term (Hb less than 70 g/L at 34 weeks' gestation or more) (ALL)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
28 Severe anaemia at postpartum (Hb less than 80 g/L) (ALL)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
29 Puerperal infection (ALL)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
30 Antepartum haemorrhage (ALL)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
31 Postpartum haemorrhage (ALL)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
32 Transfusion provided (ALL)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
33 Constipation (ALL)	1	188	Risk Ratio (M-H, Random, 95% CI)	0.77 [0.55, 1.07]
34 Nausea (ALL)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
35 Heartburn (ALL)	1	188	Risk Ratio (M-H, Random, 95% CI)	1.49 [0.95, 2.34]
36 Vomiting (ALL)	1	188	Risk Ratio (M-H, Random, 95% CI)	1.13 [0.58, 2.20]
37 Diarrhoea (ALL)	1	188	Risk Ratio (M-H, Random, 95% CI)	0.53 [0.29, 0.96]
38 Maternal wellbeing/satisfaction (ALL)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
39 Placental abruption (ALL)	1	782	Risk Ratio (M-H, Random, 95% CI)	1.81 [0.46, 7.20]
40 Premature rupture of membranes (ALL)	1	782	Risk Ratio (M-H, Random, 95% CI)	0.79 [0.44, 1.41]
41 Pre-eclampsia (ALL)	1	782	Risk Ratio (M-H, Random, 95% CI)	1.45 [0.67, 3.16]

Analysis 1.1. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 1 Low birthweight (less than 2500 g) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 1 Low birthweight (less than 2500 g) (ALL)



Analysis 1.2. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 2 Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by gestational age at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 2 Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by gestational age at the start of supplementation

Europe PMC Funders Author Manuscripts

Europe PMC Funders Author Manuscripts



Analysis 1.3. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 3 Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by anaemia status at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 3 Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by anaemia status at the start of supplementation



Analysis 1.4. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 4 Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by dose of iron.

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 4 Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by dose of iron

Europe PMC Funders Author Manuscripts



Analysis 1.5. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 5 Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by malarial status of setting.

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 5 Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by malarial status of setting



Analysis 1.6. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 6 Birthweight (g) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 6 Birthweight (g) (ALL)

Europe PMC Funders Author Manuscripts



Analysis 1.7. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 7 Birthweight (g): SUBGROUP ANALYSIS by gestational age at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 7 Birthweight (g): SUBGROUP ANALYSIS by gestational age at the start of supplementation

Europe PMC Funders Author Manuscripts



Analysis 1.8. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 8 Birthweight (g): SUBGROUP ANALYSIS by anaemia status at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 8 Birthweight (g): SUBGROUP ANALYSIS by anaemia status at the start of supplementation

Europe PMC Funders Author Manuscripts



Analysis 1.9. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 9 Birthweight (g): SUBGROUP ANALYSIS by dose of iron.

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 9 Birthweight (g): SUBGROUP ANALYSIS by dose of iron

Europe PMC Funders Author Manuscripts



Analysis 1.10. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 10 Birthweight (g): SUBGROUP ANALYSIS by malarial status of setting.

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 10 Birthweight (g): SUBGROUP ANALYSIS by malarial status of setting

Europe PMC Funders Author Manuscripts

Europe PMC Funders Author Manuscripts



Analysis 1.11. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 11 Premature birth (less than 37 weeks of gestation) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 11 Premature birth (less than 37 weeks of gestation) (ALL)



Analysis 1.12. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 12 Premature birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by gestational age at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 12 Premature birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by gestational age at the start of supplementation



Analysis 1.13. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 13 Premature birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by anaemia status at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 13 Premature birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by anaemia status at the start of supplementation

Europe PMC Funders Author Manuscripts



Analysis 1.14. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 14 Premature birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by dose of iron.

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 14 Premature birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by dose of iron



Analysis 1.15. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 15 Premature birth (less 37 weeks of gestation): SUBGROUP ANALYSIS by malarial status of setting.

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Europe PMC Funders Author Manuscripts

Outcome: 15 Premature birth (less 37 weeks of gestation): SUBGROUP ANALYSIS by malarial status of setting



Analysis 1.16. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 16 Neonatal death (within 28 days after delivery) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 16 Neonatal death (within 28 days after delivery) (ALL)

Europe PMC Funders Author Manuscripts



Analysis 1.17. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 17 Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by gestational age at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 17 Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by gestational age at the start of supplementation

Europe PMC Funders Author Manuscripts



Analysis 1.18. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 18 Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by anaemia status at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 18 Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by anaemia status at the start of supplementation

Europe PMC Funders Author Manuscripts



Analysis 1.19. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 19 Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by dose of iron.

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 19 Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by dose of iron



Analysis 1.20. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 20 Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by malarial status of setting.

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 20 Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by malarial status of setting

Europe PMC Funders Author Manuscripts



Analysis 1.21. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 21 Congenital anomalies (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 21 Congenital anomalies (ALL)



Analysis 1.22. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or

Europe PMC Funders Author Manuscripts

placebo), Outcome 22 Congenital anomalies: SUBGROUP ANALYSIS by gestational age at the start of supplementation)

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 22 Congenital anomalies: SUBGROUP ANALYSIS by gestational age at the start of supplementation)



Analysis 1.23. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 23 Congenital anomalies: SUBGROUP ANALYSIS by anaemia status at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 23 Congenital anomalies: SUBGROUP ANALYSIS by anaemia status at the start of supplementation



Analysis 1.24. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 24 Congenital anomalies: SUBGROUP ANALYSIS by dose of iron.

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 24 Congenital anomalies: SUBGROUP ANALYSIS by dose of iron

Europe PMC Funders Author Manuscripts



Analysis 1.25. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 25 Congenital anomalies: SUBGROUP ANALYSIS by malarial status of setting.

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 25 Congenital anomalies: SUBGROUP ANALYSIS by malarial status of setting

Europe PMC Funders Author Manuscripts



Analysis 1.26. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 26 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 26 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more) (ALL)

Europe PMC Funders Author Manuscripts



Analysis 1.27. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 27 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation)

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 27 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation):



Analysis 1.28. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 28 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation)

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 28 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation)



Analysis 1.29. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 29 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron)

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Europe PMC Funders Author Manuscripts

Outcome: 29 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron)



Analysis 1.30. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 30 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting)

Review: Daily oral iron supplementation during pregnancy

Europe PMC Funders Author Manuscripts

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 30 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting)



Analysis 1.31. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 31 Maternal iron deficiency at term (as defined by as defined by trialists, based on any indicator of iron status at 37 weeks's gestation or more) (ALL)

Review: Daily oral iron supplementation during pregnancy

Europe PMC Funders Author Manuscripts

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 31 Maternal iron deficiency at term (as defined by as defined by trialists, based on any indicator of iron status at 37 weeks's gestation or more) (ALL)



Analysis 1.32. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 32 Maternal iron deficiency at term (as defined by as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 32 Maternal iron deficiency at term (as defined by as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation

Europe PMC Funders Author Manuscripts



Analysis 1.33. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 33 Maternal iron deficiency at term (as defined by as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 33 Maternal iron deficiency at term (as defined by as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation

Europe PMC Funders Author Manuscripts



Analysis 1.34. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 34 Maternal iron deficiency at term (as defined by as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron.

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 34 Maternal iron deficiency at term (as defined by as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron

Europe PMC Funders Author Manuscripts



Analysis 1.35. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 35 Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting.

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 35 Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting

Europe PMC Funders Author Manuscripts



Analysis 1.36. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 36 Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicators at 37 weeks' gestation or more) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 36 Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicators at 37 weeks' gestation or more) (ALL)

Europe PMC Funders Author Manuscripts



Analysis 1.37. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 37 Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicators at 37 weeks' gestation): SUBGROUP ANALYSIS by gestational age at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 37 Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicators at 37 weeks' gestation): SUBGROUP ANALYSIS by gestational age at the start of supplementation

Europe PMC Funders Author Manuscripts



Analysis 1.38. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 38 Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicators at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 38 Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicators at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation

Europe PMC Funders Author Manuscripts



Analysis 1.39. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 39 Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicators at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron.

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 39 Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicators at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron

Europe PMC Funders Author Manuscripts



Analysis 1.40. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 40 Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicators at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting.

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 40 Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicators at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting



Analysis 1.41. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 41 Maternal death (death while pregnant or within 42 days of termination of pregnancy) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 41 Maternal death (death while pregnant or within 42 days of termination of pregnancy) (ALL)



Analysis 1.42. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 42 Side effects (any reported throughout the intervention period) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 42 Side effects (any reported throughout the intervention period) (ALL)



Analysis 1.43. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 43 Side effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by gestational age at the start of supplementation:

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 43 Side effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by gestational age at the start of supplementation:



Analysis 1.44. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 44 Side effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by anaemia status at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 44 Side effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by anaemia status at the start of supplementation

Europe PMC Funders Author Manuscripts



Analysis 1.45. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 45 Side effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by dose of iron.

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 45 Side effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by dose of iron

Europe PMC Funders Author Manuscripts



Analysis 1.46. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 46 Side effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by malarial status of setting.

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 46 Side effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by malarial status of setting

Europe PMC Funders Author Manuscripts



Analysis 1.47. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 47 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 47 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L) (ALL)

Europe PMC Funders Author Manuscripts



Analysis 1.48. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 48 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by gestational age at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 48 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by gestational age at the start of supplementation

Europe PMC Funders Author Manuscripts



Analysis 1.49. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 49 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by anaemia status at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 49 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by anaemia status at the start of supplementation

Europe PMC Funders Author Manuscripts



Analysis 1.50. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 50 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by dose of iron.

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 50 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by dose of iron



Analysis 1.51. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 51 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by malarial status of setting.

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 51 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by malarial status of setting

Europe PMC Funders Author Manuscripts



Analysis 1.53. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 53 Infection during pregnancy (including urinary tract infections) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 53 Infection during pregnancy (including urinary tract infections) (ALL)



Europe PMC Funders Author Manuscripts

Analysis 1.54. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 54 Infection during pregnancy (including urinary tract infections): SUBGROUP ANALYSIS by gestational age at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 54 Infection during pregnancy (including urinary tract infections): SUBGROUP ANALYSIS by gestational age at the start of supplementation



Analysis 1.55. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 55 Infection during pregnancy (including urinary tract infections): SUBGROUP ANALYSIS by anaemia status at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 55 Infection during pregnancy (including urinary tract infections): SUBGROUP ANALYSIS by anaemia status at the start of supplementation



Analysis 1.56. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 56 Infection during pregnancy (including urinary tract infections): SUBGROUP ANALYSIS by dose of iron.

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 56 Infection during pregnancy (including urinary tract infections): SUBGROUP ANALYSIS by dose of iron

Europe PMC Funders Author Manuscripts



Analysis 1.57. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 57 Infection during pregnancy (including urinary tract infections): SUBGROUP ANALYSIS by malarial status of setting.

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 57 Infection during pregnancy (including urinary tract infections): SUBGROUP ANALYSIS by malarial status of setting

Europe PMC Funders Author Manuscripts



Analysis 1.58. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 58 Very low birthweight (less than 1500 g) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 58 Very low birthweight (less than 1500 g) (ALL)



Analysis 1.59. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or

placebo), Outcome 59 Very premature birth (less than 34 weeks' gestation) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 59 Very premature birth (less than 34 weeks' gestation) (ALL)



Analysis 1.60. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 60 Infant Hb concentration within the first 6 months (in g/L counting the last reported measure after birth within this period) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 60 Infant Hb concentration within the first 6 months (in g/L counting the last reported measure after birth within this period) (ALL)



Analysis 1.61. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 61 Infant serum ferritin concentration within first 6 months (in *μ*g/L counting the last reported measure after birth within this period) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 61 Infant serum ferritin concentration within first 6 months (in μ g/L counting the last reported measure after birth within this period) (ALL)



Analysis 1.62. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 62 Admission to special care unit (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Europe PMC Funders Author Manuscripts

Outcome: 62 Admission to special care unit (ALL)



Analysis 1.63. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 63 Maternal anaemia at or near term (Hb less than 110 g/L at 34 weeks' gestation or more) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 63 Maternal anaemia at or near term (Hb less than 110 g/L at 34 weeks' gestation or more) (ALL)

Europe PMC Funders Author Manuscripts



Analysis 1.64. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 64 Maternal iron deficiency at or near term (as defined by as defined by trialists, based on any indicator of iron status at 34 weeks's gestation or more)) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 64 Maternal iron deficiency at or near term (as defined by as defined by trialists, based on any indicator of iron status at 34 weeks's gestation or more)) (ALL)



Analysis 1.65. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 65 Maternal iron-deficiency anaemia at or near term (Hb less than 110 g/L and at least one additional laboratory indicators at 34 weeks' gestation or more) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 65 Maternal iron-deficiency anaemia at or near term (Hb less than 110 g/L and at least one additional laboratory indicators at 34 weeks' gestation or more) (ALL)



Europe PMC Funders Author Manuscripts

Analysis 1.66. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 66 Maternal Hb concentration at or near term (in g/L, at 34 weeks' gestation or more) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 66 Maternal Hb concentration at or near term (in g/L, at 34 weeks' gestation or more) (ALL)



(1) We have treated this as two studies here as means were provided for several arms in this trial

Analysis 1.67. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 67 Maternal Hb concentration within 6 wk postpartum (in g/L) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 67 Maternal Hb concentration within 6 wk postpartum (in g/L) (ALL)



Analysis 1.68. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 68 Maternal high haemoglobin concentrations during second or third trimester (Hb more than 130 g/L) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 68 Maternal high haemoglobin concentrations during second or third trimester (Hb more than 130 g/L) (ALL)

Europe PMC Funders Author Manuscripts



Analysis 1.69. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 69 Maternal high haemoglobin concentrations at or near term (Hb more than 130 g/L at 34 weeks' gestation or more) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 69 Maternal high haemoglobin concentrations at or near term (Hb more than 130 g/L at 34 weeks' gestation or more) (ALL)

Europe PMC Funders Author Manuscripts



Analysis 1.70. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 70 Maternal severe anaemia at or near term (Hb less than 70 g/L at 34 weeks' gestation or more) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 70 Maternal severe anaemia at or near term (Hb less than 70 g/L at 34 weeks' gestation or more) (ALL)

Europe PMC Funders Author Manuscripts



Analysis 1.71. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 71 Severe anaemia at postpartum (Hb less than 80 g/L) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 71 Severe anaemia at postpartum (Hb less than 80 g/L) (ALL)



Analysis 1.72. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 72 Moderate anaemia at postpartum (Hb more than 80 g/L and less than 110 g/L) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 72 Moderate anaemia at postpartum (Hb more than 80 g/L and less than 110 g/L) (ALL)



Analysis 1.73. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 73 Puerperal infection (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 73 Puerperal infection (ALL)



Analysis 1.74. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 74 Antepartum haemorrhage (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 74 Antepartum haemorrhage (ALL)



Analysis 1.75. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 75 Postpartum haemorrhage (ALL)

Review: Daily oral iron supplementation during pregnancy

Europe PMC Funders Author Manuscripts

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 75 Postpartum haemorrhage (ALL)



Analysis 1.76. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 76 Transfusion provided (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 76 Transfusion provided (ALL)



Europe PMC Funders Author Manuscripts

Analysis 1.77. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 77 Diarrhoea (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 77 Diarrhoea (ALL)



Analysis 1.78. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 78 Constipation (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 78 Constipation (ALL)



Analysis 1.79. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 79 Nausea (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 79 Nausea (ALL)



Analysis 1.80. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 80 Heartburn (ALL)

Review: Daily oral iron supplementation during pregnancy

Europe PMC Funders Author Manuscripts

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 80 Heartburn (ALL)



Analysis 1.81. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 81 Vomiting (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 81 Vomiting (ALL)



Europe PMC Funders Author Manuscripts

Analysis 1.82. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 82 Maternal wellbeing/satisfaction (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 82 Maternal wellbeing/satisfaction (ALL)



Analysis 1.83. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 83 Placental abruption (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 83 Placental abruption (ALL)



Analysis 1.84. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 84 Premature rupture of membranes (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 84 Premature rupture of membranes (ALL)



Analysis 1.85. Comparison 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo), Outcome 85 Pre-eclampsia (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 1 Any supplements containing iron versus same supplements without iron or no treatment/placebo (no iron or placebo)

Outcome: 85 Pre-eclampsia (ALL)



Analysis 2.1. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo), Outcome 1 Low birthweight (less than 2500 g) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 1 Low birthweight (less than 2500 g) (ALL)



Analysis 2.2. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo), Outcome 2 Birthweight (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 2 Birthweight (ALL)



Analysis 2.3. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo), Outcome 3 Premature birth (less than 37 weeks of gestation) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 3 Premature birth (less than 37 weeks of gestation) (ALL)



Analysis 2.4. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo), Outcome 4 Premature birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by gestation at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 4 Premature birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by gestation at the start of supplementation



Analysis 2.5. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo), Outcome 5 Premature birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by anaemia status at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 5 Premature birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by anaemia status at the start of supplementation

Europe PMC Funders Author Manuscripts



Analysis 2.6. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo), Outcome 6 Premature birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by dose of iron.

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 6 Premature birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by dose of iron

Europe PMC Funders Author Manuscripts

Europe PMC Funders Author Manuscripts



Analysis 2.7. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo), Outcome 7 Premature birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by malarial status of settings.

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 7 Premature birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by malarial status of settings



Analysis 2.8. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo), Outcome 8 Neonatal death (within 28 days after delivery) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 8 Neonatal death (within 28 days after delivery) (ALL)



Analysis 2.9. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid

Europe PMC Funders Author Manuscripts

or placebo), Outcome 9 Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by gestation at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 9 Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by gestation at the start of supplementation



Analysis 2.10. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo), Outcome 10 Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by anaemia status at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 10 Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by anaemia status at the start of supplementation



Analysis 2.11. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo), Outcome 11 Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by dose of iron.

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 11 Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by dose of iron

Europe PMC Funders Author Manuscripts



Analysis 2.12. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo), Outcome 12 Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by malarial status at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 12 Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by malarial status at the start of supplementation

Europe PMC Funders Author Manuscripts



Analysis 2.13. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo), Outcome 13 Congenital anomalies (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 13 Congenital anomalies (ALL)



Analysis 2.14. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic

Europe PMC Funders Author Manuscripts

acid or placebo), Outcome 14 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 14 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more) (ALL)



Analysis 2.15. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo), Outcome 15 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestation at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 15 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestation at the start of supplementation

Europe PMC Funders Author Manuscripts

Analysis 2.16. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo), Outcome 16 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 16 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation

Analysis 2.17. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo), Outcome 17 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron.

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 17 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron

Europe PMC Funders Author Manuscripts

Analysis 2.18. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo), Outcome 18 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting.

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 18 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting

Europe PMC Funders Author Manuscripts



Analysis 2.19. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo), Outcome 19 Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 19 Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more) (ALL)



Analysis 2.20. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic

Europe PMC Funders Author Manuscripts

acid or placebo), Outcome 20 Maternal iron deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicators at 37 weeks' gestation or more) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 20 Maternal iron deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicators at 37 weeks' gestation or more) (ALL)



Analysis 2.21. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo), Outcome 21 Maternal death (death while pregnant or within 42 days of termination of pregnancy) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 21 Maternal death (death while pregnant or within 42 days of termination of pregnancy) (ALL)



Analysis 2.22. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo), Outcome 22 Side effects (any reported throughout the intervention period) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 22 Side effects (any reported throughout the intervention period) (ALL)



Analysis 2.23. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo), Outcome 23 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 23 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L) (ALL)



Analysis 2.24. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo), Outcome 24 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by gestation at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 24 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by gestation at the start of supplementation

Europe PMC Funders Author Manuscripts



Analysis 2.25. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo), Outcome 25 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by anaemia status at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 25 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by anaemia status at the start of supplementation

Europe PMC Funders Author Manuscripts



Analysis 2.26. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo), Outcome 26 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by dose of iron.

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 26 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by dose of iron

Europe PMC Funders Author Manuscripts

Analysis 2.27. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo), Outcome 27 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by malarial status of setting.

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 27 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by malarial status of setting



Analysis 2.29. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo), Outcome 29 Infection during pregnancy (including urinary tract infections) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 29 Infection during pregnancy (including urinary tract infections) (ALL)



Europe PMC Funders Author Manuscripts

Analysis 2.30. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo), Outcome 30 Very low birthweight (less than 1500 g) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 30 Very low birthweight (less than 1500 g) (ALL)



Analysis 2.31. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo), Outcome 31 Very premature birth (less than 34 weeks' gestation) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 31 Very premature birth (less than 34 weeks' gestation) (ALL)



Analysis 2.32. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo), Outcome 32 Admission to special care unit (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 32 Admission to special care unit (ALL)



Analysis 2.33. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo), Outcome 33 Maternal anaemia at or near term (Hb less than 110 g/L at 34 weeks' gestation or more) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 33 Maternal anaemia at or near term (Hb less than 110 g/L at 34 weeks' gestation or more) (ALL)

Europe PMC Funders Author Manuscripts



Analysis 2.34. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo), Outcome 34 Maternal iron deficiency at or near term (as defined by trialists, based on any indicator of iron status at 34 weeks' gestation or more) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 34 Maternal iron deficiency at or near term (as defined by trialists, based on any indicator of iron status at 34 weeks' gestation or more) (ALL)



Analysis 2.35. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo), Outcome 35 Maternal iron-deficiency anaemia at or near

Europe PMC Funders Author Manuscripts

term (Hb less than 110 g/L and at least one additional laboratory indicators at 34 weeks' gestation or more) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 35 Maternal iron-deficiency anaemia at or near term (Hb less than 110 g/L and at least one additional laboratory indicators at 34 weeks' gestation or more) (ALL)



Analysis 2.36. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo), Outcome 36 Maternal Hb concentration at or near term (in g/L, at 34 weeks' gestation or more) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 36 Maternal Hb concentration at or near term (in g/L, at 34 weeks' gestation or more) (ALL)



Analysis 2.37. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo), Outcome 37 Maternal Hb concentration within 6 wk postpartum (in g/L) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 37 Maternal Hb concentration within 6 wk postpartum (in g/L) (ALL)



Analysis 2.38. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo), Outcome 38 Maternal high haemoglobin concentrations during second or third trimester (Hb more than 130 g/L) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 38 Maternal high haemoglobin concentrations during second or third trimester (Hb more than 130 g/L) (ALL)



Analysis 2.39. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo), Outcome 39 Maternal high haemoglobin concentrations at or near term (Hb more than 130 g/L at 34 weeks' gestation or more) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 39 Maternal high haemoglobin concentrations at or near term (Hb more than 130 g/L at 34 weeks' gestation or more) (ALL)



Analysis 2.40. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo), Outcome 40 Moderate anaemia at postpartum (Hb more than 80 g/L and less than 110 g/L) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 40 Moderate anaemia at postpartum (Hb more than 80 g/L and less than 110 g/L) (ALL)



Analysis 2.41. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo), Outcome 41 Maternal severe anaemia at or near term (Hb less than 70 g/L at 34 weeks' gestation or more) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 41 Maternal severe anaemia at or near term (Hb less than 70 g/L at 34 weeks' gestation or more) (ALL)



Analysis 2.42. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic

acid or placebo), Outcome 42 Severe anaemia at postpartum (Hb less than 80 g/L) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 42 Severe anaemia at postpartum (Hb less than 80 g/L) (ALL)



Analysis 2.43. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo), Outcome 43 Puerperal infection (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 43 Puerperal infection (ALL)



Europe PMC Funders Author Manuscripts

Analysis 2.44. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo), Outcome 44 Antepartum haemorrhage (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 44 Antepartum haemorrhage (ALL)



Analysis 2.46. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo), Outcome 46 Placental abruption (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 46 Placental abruption (ALL)



Analysis 2.47. Comparison 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo), Outcome 47 Pre-eclampsia (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 2 Any supplements containing iron and folic acid versus same supplements without iron nor folic acid (no iron nor folic acid or placebo)

Outcome: 47 Pre-eclampsia (ALL)



Analysis 3.1. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 1 Low birthweight (less than 2500 g) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 1 Low birthweight (less than 2500 g) (ALL)



Analysis 3.2. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 2 Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by gestational age at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 2 Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by gestational age at the start of supplementation



Analysis 3.3. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 3 Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by anaemia status at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 3 Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by anaemia status at the start of supplementation



Analysis 3.4. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 4 Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by dose of iron.

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 4 Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by dose of iron

Europe PMC Funders Author Manuscripts



Analysis 3.5. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 5 Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by malarial status of setting.

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 5 Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by malarial status of setting

Europe PMC Funders Author Manuscripts



Analysis 3.6. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 6 Birthweight (g) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 6 Birthweight (g) (ALL)



Europe PMC Funders Author Manuscripts

Analysis 3.7. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 7 Birthweight (g): SUBGROUP ANALYSIS by gestational age at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 7 Birthweight (g): SUBGROUP ANALYSIS by gestational age at the start of supplementation



Analysis 3.8. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 8 Birthweight (g): SUBGROUP ANALYSIS by anaemia status at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 8 Birthweight (g): SUBGROUP ANALYSIS by anaemia status at the start of supplementation



Analysis 3.9. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 9 Birthweight (g): SUBGROUP ANALYSIS by dose of iron.

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 9 Birthweight (g): SUBGROUP ANALYSIS by dose of iron

Europe PMC Funders Author Manuscripts



Analysis 3.10. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 10 Birthweight (g): SUBGROUP ANALYSIS by malarial status of setting.

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 10 Birthweight (g): SUBGROUP ANALYSIS by malarial status of setting

Europe PMC Funders Author Manuscripts



Analysis 3.11. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 11 Premature birth (less than 37 weeks of gestation) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 11 Premature birth (less than 37 weeks of gestation) (ALL)



Analysis 3.12. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 12 Premature birth (less 37 weeks of gestation): SUBGROUP ANALYSIS by gestational age at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 12 Premature birth (less 37 weeks of gestation): SUBGROUP ANALYSIS by gestational age at the start of supplementation



Analysis 3.13. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 13 Premature birth (less 37 weeks of gestation): SUBGROUP ANALYSIS by anaemia status at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 13 Premature birth (less 37 weeks of gestation): SUBGROUP ANALYSIS by anaemia status at the start of supplementation



Analysis 3.14. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 14 Premature birth (less 37 weeks of gestation): SUBGROUP ANALYSIS by dose of iron.

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 14 Premature birth (less 37 weeks of gestation): SUBGROUP ANALYSIS by dose of iron

Europe PMC Funders Author Manuscripts



Analysis 3.15. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 15 Premature birth (less 37 weeks of gestation): SUBGROUP ANALYSIS by malarial status of setting.

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 15 Premature birth (less 37 weeks of gestation): SUBGROUP ANALYSIS by malarial status of setting



Analysis 3.16. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 16 Neonatal death (within 28 days after delivery) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 16 Neonatal death (within 28 days after delivery) (ALL)



Analysis 3.17. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 17 Congenital anomalies (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 17 Congenital anomalies (ALL)



Analysis 3.18. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 18 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 18 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more) (ALL)



Europe PMC Funders Author Manuscripts

Europe PMC Funders Author Manuscripts

Analysis 3.19. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 19 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 19 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation



Analysis 3.20. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 20 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 20 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation



Europe PMC Funders Author Manuscripts

Analysis 3.21. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 21 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron.

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 21 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron



Analysis 3.22. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 22 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting.

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 22 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting



Analysis 3.23. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 23 Maternal iron deficiency at term (as defined

by trialists, based on any indicator of iron status at 37 weeks' gestation or more) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 23 Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more) (ALL)



Analysis 3.24. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 24 Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 24 Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation

Europe PMC Funders Author Manuscripts



Analysis 3.25. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 25 Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 25 Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation

Europe PMC Funders Author Manuscripts



Analysis 3.26. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 26 Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron.

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 26 Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron



Analysis 3.27. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 27 Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting.

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 27 Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting

Europe PMC Funders Author Manuscripts



Analysis 3.28. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 28 Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicators at 37 weeks' gestation or more) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 28 Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicators at 37 weeks' gestation or more) (ALL)



Analysis 3.29. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 29 Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicators at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 29 Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicators at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation

Europe PMC Funders Author Manuscripts



Analysis 3.30. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 30 Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicators at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 30 Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicators at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation

Europe PMC Funders Author Manuscripts



Analysis 3.31. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 31 Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicators at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron.

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 31 Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicators at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron

Europe PMC Funders Author Manuscripts



Analysis 3.32. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 32 Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicators at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting.

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 32 Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicators at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting

Europe PMC Funders Author Manuscripts



Analysis 3.33. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 33 Maternal death (death while pregnant or within 42 days of termination of pregnancy) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 33 Maternal death (death while pregnant or within 42 days of termination of pregnancy) (ALL)



Analysis 3.34. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 34 Side effects (any reported throughout the intervention period) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 34 Side effects (any reported throughout the intervention period) (ALL)



Analysis 3.35. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 35 Side effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by gestational age at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 35 Side effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by gestational age at the start of supplementation



Analysis 3.36. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 36 Side effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by anaemia status at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 36 Side effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by anaemia status at the start of supplementation

Europe PMC Funders Author Manuscripts



Analysis 3.37. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 37 Side effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by dose of iron.

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 37 Side effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by dose of iron

Europe PMC Funders Author Manuscripts



Analysis 3.38. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 38 Side effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by malarial status of setting.

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 38 Side effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by malarial status of setting

Europe PMC Funders Author Manuscripts



Analysis 3.39. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 39 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 39 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L) (ALL)

Europe PMC Funders Author Manuscripts



Analysis 3.40. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 40 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by gestational age at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 40 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by gestational age at the start of supplementation

Europe PMC Funders Author Manuscripts



Analysis 3.41. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 41 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by anaemia status age at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 41 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by anaemia status age at the start of supplementation

Europe PMC Funders Author Manuscripts



Analysis 3.42. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 42 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by dose of iron.

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 42 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by dose of iron

Europe PMC Funders Author Manuscripts



Analysis 3.43. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 43 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by malarial status of setting.

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 43 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by malarial status of setting

Europe PMC Funders Author Manuscripts



Analysis 3.45. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 45 Infection during pregnancy (including urinary tract infections) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 45 Infection during pregnancy (including urinary tract infections) (ALL)



Europe PMC Funders Author Manuscripts

Analysis 3.46. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 46 Very low birthweight (less than 1500 g) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 46 Very low birthweight (less than 1500 g) (ALL)



Analysis 3.47. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 47 Very premature birth (less than 34 weeks' gestation) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 47 Very premature birth (less than 34 weeks' gestation) (ALL)



Analysis 3.48. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 48 Infant Hb concentration in the first 6 months (in g/L, counting the last reported measure after birth within this period) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 48 Infant Hb concentration in the first 6 months (in g/L, counting the last reported measure after birth within this period) (ALL)



Analysis 3.49. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 49 Infant serum ferritin concentration in the first 6 months (in *μ*g/L, counting the last reported measure after birth within this period) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 49 Infant serum ferritin concentration in the first 6 months (in μ g/L, counting the last reported measure after birth within this period) (ALL)



Analysis 3.50. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 50 Admission to special care unit (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 50 Admission to special care unit (ALL)



Analysis 3.51. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 51 Maternal anaemia at or near term (Hb less than 110 g/L at 34 weeks' gestation or more) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 51 Maternal anaemia at or near term (Hb less than 110 g/L at 34 weeks' gestation or more) (ALL)

Europe PMC Funders Author Manuscripts



Analysis 3.52. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 52 Maternal iron deficiency at or near term (as defined by trialists, based on any indicator of iron status at 34 weeks' gestation or more) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 52 Maternal iron deficiency at or near term (as defined by trialists, based on any indicator of iron status at 34 weeks' gestation or more) (ALL)

Europe PMC Funders Author Manuscripts



Analysis 3.53. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 53 Maternal iron-deficiency anaemia at or near term (Hb less than 110 g/L and at least one additional laboratory indicators at 34 weeks' gestation or more) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 53 Maternal iron-deficiency anaemia at or near term (Hb less than 110 g/L and at least one additional laboratory indicators at 34 weeks' gestation or more) (ALL)



Europe PMC Funders Author Manuscripts

Europe PMC Funders Author Manuscripts

Analysis 3.54. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 54 Maternal Hb concentration at or near term (in g/L, at 34 weeks' gestation or more) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 54 Maternal Hb concentration at or near term (in g/L, at 34 weeks' gestation or more) (ALL)



Study or subgroup	iron supplements N	Mean(SD)	no treatment/placebo N	Mean(SD)	Mean Difference IV,Random,95% CI	Weight	Mean Difference IV,Random,95% CI
Van Eijk 1978	15	132.13 (11.27)	15	112.79 (16.11)		3.6 %	19.34 [9.39, 29.29]
Puolakka 1980	16	132 (12)	15	111 (9)		4.8 %	21.00 [13.56, 28.44]
Wallenburg 1983	18	128.9 (11.3)	20	125.6 (11.3)		4.9 %	3.30 [-3.90, 10.50]
Buytaert 1983	24	127.29 (12.8)	21	124.07 (8.05)		5.5 %	3.22 [-2.95, 9.39]
Cantlie 1971	15	124 (6)	12	110 (9)		5.6 %	14.00 [8.07, 19.93]
Batu 1976	30	113 (10)	22	97 (11)		5.7 %	16.00 [10.17, 21.83]
Romslo 1983	22	126 (8)	23	113 (10)		6.0 %	13.00 [7.72, 18.28]
De Benaze 1989	44	130 (10)	25	122 (10)		6.2 %	8.00 [3.09, 12.91]
Eskeland 1997	24	125.7 (7.8)	21	112.8 (6.5)		6.6 %	12.90 [8.72, 17.08]
Chanarin 1971	49	124 (9.8)	46	114 (9.5)		6.7 %	10.00 [6.12, 13.88]
Cogswell 2003	90	121.4 (10.39)	62	121.7 (10.48)		7.0 %	-0.30 [-3.68, 3.08]
Falahi 2010	70	123.2 (8.8)	78	120.9 (7.9)		7.3 %	2.30 [-0.41, 5.01]
Makrides 2003	200	127 (13)	193	120 (12)		7.4 %	7.00 [4.53, 9.47]
Milman 1991	99	128.9 (8)	107	118.9 (10)		7.4 %	10.00 [7.54, 12.46]
Tura 1989	129	121 (8)	112	119 (10)		7.5 %	2.00 [-0.31, 4.31]
Ziaei 2008	114	138.8 (4.5)	120	127.8 (4.7)		7.8 %	11.00 [9.82, 12.18]
Total (95% CI)	**959**		**892**			**100.0 %**	**8.95 [6.37, 11.53]**

Heterogeneity: $Tau^2 = 21.70$; $Chi^2 = 134.32$, df = 15 (P<0.00001); $I^2 = 89\%$
Test for overall effect: Z = 6.81 (P < 0.00001)
Test for subgroup differences: Not applicable

-100 -50 0 50 100
no treatment/placebo iron supplements

Analysis 3.55. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 55 Maternal Hb concentration within 6 wk postpartum (in g/L) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 55 Maternal Hb concentration within 6 wk postpartum (in g/L) (ALL)



Analysis 3.56. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 56 Maternal high haemoglobin concentrations during second or third trimester (Hb more than 130 g/L) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 56 Maternal high haemoglobin concentrations during second or third trimester (Hb more than 130 g/L) (ALL)



Analysis 3.57. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 57 Maternal high haemoglobin concentrations at or near term (Hb more than 130 g/L at 34 weeks' gestation or more) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 57 Maternal high haemoglobin concentrations at or near term (Hb more than 130 g/L at 34 weeks' gestation or more) (ALL)



Analysis 3.58. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 58 Moderate anaemia at postpartum (Hb more than 80 g/L and less than 110 g/L) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 58 Moderate anaemia at postpartum (Hb more than 80 g/L and less than 110 g/L) (ALL)



Europe PMC Funders Author Manuscripts

Analysis 3.59. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 59 Maternal severe anaemia at or near term (Hb less than 70 g/L at 34 weeks' gestation or more) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 59 Maternal severe anaemia at or near term (Hb less than 70 g/L at 34 weeks' gestation or more) (ALL)



Analysis 3.60. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 60 Severe anaemia at postpartum (Hb less than 80 g/L) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 60 Severe anaemia at postpartum (Hb less than 80 g/L) (ALL)



Analysis 3.61. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 61 Puerperal infection (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 61 Puerperal infection (ALL)



Analysis 3.62. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 62 Antepartum haemorrhage (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 62 Antepartum haemorrhage (ALL)

Europe PMC Funders Author Manuscripts



Analysis 3.63. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 63 Postpartum haemorrhage (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 63 Postpartum haemorrhage (ALL)



Analysis 3.64. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 64 Transfusion provided (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 64 Transfusion provided (ALL)

Europe PMC Funders Author Manuscripts



Analysis 3.65. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 65 Diarrhoea (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 65 Diarrhoea (ALL)



Analysis 3.66. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 66 Constipation (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 66 Constipation (ALL)

Europe PMC Funders Author Manuscripts



Analysis 3.67. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 67 Nausea (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 67 Nausea (ALL)



Analysis 3.68. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 68 Heartburn (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 68 Heartburn (ALL)

Europe PMC Funders Author Manuscripts



Analysis 3.69. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 69 Vomiting (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 69 Vomiting (ALL)



Analysis 3.70. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 70 Maternal wellbeing/satisfaction (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 70 Maternal wellbeing/satisfaction (ALL)



Analysis 3.71. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 71 Placental abruption (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 71 Placental abruption (ALL)



Analysis 3.73. Comparison 3 Supplementation with iron alone versus no treatment/placebo, Outcome 73 Pre-eclampsia (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 3 Supplementation with iron alone versus no treatment/placebo

Outcome: 73 Pre-eclampsia (ALL)

Europe PMC Funders Author Manuscripts



Analysis 4.1. Comparison 4 Supplementation with iron+folic acid versus no treatment/placebo, Outcome 1 Low birthweight (less than 2500 g) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 4 Supplementation with iron+folic acid versus no treatment/placebo

Outcome: 1 Low birthweight (less than 2500 g) (ALL)



Analysis 4.2. Comparison 4 Supplementation with iron+folic acid versus no treatment/placebo, Outcome 2 Birthweight (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 4 Supplementation with iron+folic acid versus no treatment/placebo

Outcome: 2 Birthweight (ALL)

Europe PMC Funders Author Manuscripts



Analysis 4.3. Comparison 4 Supplementation with iron+folic acid versus no treatment/placebo, Outcome 3 Premature birth (less than 37 weeks of gestation) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 4 Supplementation with iron+folic acid versus no treatment/placebo

Outcome: 3 Premature birth (less than 37 weeks of gestation) (ALL)



Analysis 4.4. Comparison 4 Supplementation with iron+folic acid versus no treatment/placebo, Outcome 4 Premature birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by gestational age at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 4 Supplementation with iron+folic acid versus no treatment/placebo

Outcome: 4 Premature birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by gestational age at the start of supplementation

Europe PMC Funders Author Manuscripts



Analysis 4.5. Comparison 4 Supplementation with iron+folic acid versus no treatment/placebo, Outcome 5 Premature birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by anaemia status at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 4 Supplementation with iron+folic acid versus no treatment/placebo

Outcome: 5 Premature birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by anaemia status at the start of supplementation

Europe PMC Funders Author Manuscripts

Europe PMC Funders Author Manuscripts

Analysis 4.6. Comparison 4 Supplementation with iron+folic acid versus no treatment/placebo, Outcome 6 Premature birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by dose of iron.

Review: Daily oral iron supplementation during pregnancy

Comparison: 4 Supplementation with iron+folic acid versus no treatment/placebo

Outcome: 6 Premature birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by dose of iron



Analysis 4.7. Comparison 4 Supplementation with iron+folic acid versus no treatment/placebo, Outcome 7 Premature birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by malarial status of setting.

Review: Daily oral iron supplementation during pregnancy

Comparison: 4 Supplementation with iron+folic acid versus no treatment/placebo

Outcome: 7 Premature birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by malarial status of setting



Analysis 4.8. Comparison 4 Supplementation with iron+folic acid versus no treatment/placebo, Outcome 8 Neonatal death (within 28 days after delivery) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 4 Supplementation with iron+folic acid versus no treatment/placebo

Outcome: 8 Neonatal death (within 28 days after delivery) (ALL)



Analysis 4.9. Comparison 4 Supplementation with iron+folic acid versus no treatment/placebo, Outcome 9 Neonatal death (within 28 days after

Europe PMC Funders Author Manuscripts

delivery): SUBGROUP ANALYSIS by gestational age at start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 4 Supplementation with iron+folic acid versus no treatment/placebo

Outcome: 9 Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by gestational age at start of supplementation



Analysis 4.10. Comparison 4 Supplementation with iron+folic acid versus no treatment/placebo, Outcome 10 Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by anaemia status at start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 4 Supplementation with iron+folic acid versus no treatment/placebo

Outcome: 10 Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by anaemia status at start of supplementation



Analysis 4.11. Comparison 4 Supplementation with iron+folic acid versus no treatment/placebo, Outcome 11 Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by dose of iron.

Review: Daily oral iron supplementation during pregnancy

Comparison: 4 Supplementation with iron+folic acid versus no treatment/placebo

Outcome: 11 Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by dose of iron

Europe PMC Funders Author Manuscripts

Europe PMC Funders Author Manuscripts



Analysis 4.12. Comparison 4 Supplementation with iron+folic acid versus no treatment/placebo, Outcome 12 Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by malarial status of setting.

Review: Daily oral iron supplementation during pregnancy

Comparison: 4 Supplementation with iron+folic acid versus no treatment/placebo

Outcome: 12 Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by malarial status of setting



Analysis 4.13. Comparison 4 Supplementation with iron+folic acid versus no treatment/placebo, Outcome 13 Congenital anomalies (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 4 Supplementation with iron+folic acid versus no treatment/placebo

Outcome: 13 Congenital anomalies (ALL)



Analysis 4.14. Comparison 4 Supplementation with iron+folic acid versus no treatment/placebo, Outcome 14 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 4 Supplementation with iron+folic acid versus no treatment/placebo

Outcome: 14 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more) (ALL)



Analysis 4.15. Comparison 4 Supplementation with iron+folic acid versus no treatment/placebo, Outcome 15 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 4 Supplementation with iron+folic acid versus no treatment/placebo

Outcome: 15 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation

Europe PMC Funders Author Manuscripts

Analysis 4.16. Comparison 4 Supplementation with iron+folic acid versus no treatment/placebo, Outcome 16 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 4 Supplementation with iron+folic acid versus no treatment/placebo

Outcome: 16 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation

Europe PMC Funders Author Manuscripts



Analysis 4.17. Comparison 4 Supplementation with iron+folic acid versus no treatment/placebo, Outcome 17 Maternal anaemia at term (Hb less than 110 g/Lat 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron.

Review: Daily oral iron supplementation during pregnancy

Comparison: 4 Supplementation with iron+folic acid versus no treatment/placebo

Outcome: 17 Maternal anaemia at term (Hb less than 110 g/Lat 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron



Analysis 4.18. Comparison 4 Supplementation with iron+folic acid versus no treatment/placebo, Outcome 18 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting.

Review: Daily oral iron supplementation during pregnancy

Comparison: 4 Supplementation with iron+folic acid versus no treatment/placebo

Outcome: 18 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting



Analysis 4.19. Comparison 4 Supplementation with iron+folic acid versus no treatment/placebo, Outcome 19 Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 4 Supplementation with iron+folic acid versus no treatment/placebo

Outcome: 19 Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more) (ALL)



Analysis 4.20. Comparison 4 Supplementation with iron+folic acid versus no treatment/placebo, Outcome 20 Maternal iron-deficiency anaemia at

term (Hb less than 110 g/L and at least one additional laboratory indicators at 37 weeks' gestation or more) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 4 Supplementation with iron+folic acid versus no treatment/placebo

Outcome: 20 Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicators at 37 weeks' gestation or more) (ALL)



Analysis 4.21. Comparison 4 Supplementation with iron+folic acid versus no treatment/placebo, Outcome 21 Maternal death (death while pregnant or within 42 days of termination of pregnancy) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 4 Supplementation with iron+folic acid versus no treatment/placebo

Outcome: 21 Maternal death (death while pregnant or within 42 days of termination of pregnancy) (ALL)



Analysis 4.22. Comparison 4 Supplementation with iron+folic acid versus no treatment/placebo, Outcome 22 Side effects (any reported throughout the intervention period) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 4 Supplementation with iron+folic acid versus no treatment/placebo

Outcome: 22 Side effects (any reported throughout the intervention period) (ALL)



Analysis 4.23. Comparison 4 Supplementation with iron+folic acid versus no treatment/placebo, Outcome 23 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 4 Supplementation with iron+folic acid versus no treatment/placebo

Outcome: 23 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L) (ALL)



Analysis 4.25. Comparison 4 Supplementation with iron+folic acid versus no treatment/placebo, Outcome 25 Infection during pregnancy (including urinary tract infections) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 4 Supplementation with iron+folic acid versus no treatment/placebo

Outcome: 25 Infection during pregnancy (including urinary tract infections) (ALL)



Analysis 4.26. Comparison 4 Supplementation with iron+folic acid versus no treatment/placebo, Outcome 26 Very low birthweight (less than 1500 g) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 4 Supplementation with iron+folic acid versus no treatment/placebo

Outcome: 26 Very low birthweight (less than 1500 g) (ALL)



Analysis 4.27. Comparison 4 Supplementation with iron+folic acid versus no treatment/placebo, Outcome 27 Very premature birth (less than 34 weeks' gestation) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 4 Supplementation with iron+folic acid versus no treatment/placebo

Outcome: 27 Very premature birth (less than 34 weeks' gestation) (ALL)



Analysis 4.30. Comparison 4 Supplementation with iron+folic acid versus no treatment/placebo, Outcome 30 Admission to special care unit (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 4 Supplementation with iron+folic acid versus no treatment/placebo

Outcome: 30 Admission to special care unit (ALL)



Analysis 4.31. Comparison 4 Supplementation with iron+folic acid versus no treatment/placebo, Outcome 31 Maternal anaemia at or near term (Hb less than 110 g/L at 34 weeks' gestation or more) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 4 Supplementation with iron+folic acid versus no treatment/placebo

Outcome: 31 Maternal anaemia at or near term (Hb less than 110 g/L at 34 weeks' gestation or more) (ALL)



Analysis 4.32. Comparison 4 Supplementation with iron+folic acid versus no treatment/placebo, Outcome 32 Maternal iron deficiency at or near term (as defined by trialists, based on any indicator of iron status at 34 weeks' gestation or more) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 4 Supplementation with iron+folic acid versus no treatment/placebo

Outcome: 32 Maternal iron deficiency at or near term (as defined by trialists, based on any indicator of iron status at 34 weeks' gestation or more) (ALL)



Analysis 4.33. Comparison 4 Supplementation with iron+folic acid versus no treatment/placebo, Outcome 33 Maternal iron-deficiency anaemia at or

Europe PMC Funders Author Manuscripts

near term (Hb less than 110 g/L and at least one additional laboratory indicators at 34 weeks' gestation or more) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 4 Supplementation with iron+folic acid versus no treatment/placebo

Outcome: 33 Maternal iron-deficiency anaemia at or near term (Hb less than 110 g/L and at least one additional laboratory indicators at 34 weeks' gestation or more) (ALL)



Analysis 4.34. Comparison 4 Supplementation with iron+folic acid versus no treatment/placebo, Outcome 34 Maternal Hb concentration at term or near term (in g/L, at 34 weeks' gestation or more) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 4 Supplementation with iron+folic acid versus no treatment/placebo

Outcome: 34 Maternal Hb concentration at term or near term (in g/L, at 34 weeks' gestation or more) (ALL)



Europe PMC Funders Author Manuscripts

Analysis 4.35. Comparison 4 Supplementation with iron+folic acid versus no treatment/placebo, Outcome 35 Maternal Hb concentration within 6 wk postpartum (g/L) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 4 Supplementation with iron+folic acid versus no treatment/placebo

Outcome: 35 Maternal Hb concentration within 6 wk postpartum (g/L) (ALL)



Analysis 4.36. Comparison 4 Supplementation with iron+folic acid versus no treatment/placebo, Outcome 36 Maternal high haemoglobin concentrations during second or third trimester (Hb more than 130 g/L) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 4 Supplementation with iron+folic acid versus no treatment/placebo

Outcome: 36 Maternal high haemoglobin concentrations during second or third trimester (Hb more than 130 g/L) (ALL)



Analysis 4.37. Comparison 4 Supplementation with iron+folic acid versus no treatment/placebo, Outcome 37 Maternal high haemoglobin concentrations at or near term (Hb more than 130 g/L at 34 weeks' gestation or more) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 4 Supplementation with iron+folic acid versus no treatment/placebo

Outcome: 37 Maternal high haemoglobin concentrations at or near term (Hb more than 130 g/L at 34 weeks' gestation or more) (ALL)



Analysis 4.38. Comparison 4 Supplementation with iron+folic acid versus no treatment/placebo, Outcome 38 Moderate anaemia at postpartum (Hb more than 80 g/L and less than 110 g/L) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 4 Supplementation with iron+folic acid versus no treatment/placebo

Outcome: 38 Moderate anaemia at postpartum (Hb more than 80 g/L and less than 110 g/L) (ALL)



Analysis 4.39. Comparison 4 Supplementation with iron+folic acid versus no treatment/placebo, Outcome 39 Maternal severe anaemia at term or near (Hb less than 70 g/L at 34 weeks' gestation or more) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 4 Supplementation with iron+folic acid versus no treatment/placebo

Outcome: 39 Maternal severe anaemia at term or near (Hb less than 70 g/L at 34 weeks' gestation or more) (ALL)



Analysis 4.40. Comparison 4 Supplementation with iron+folic acid versus no treatment/placebo, Outcome 40 Severe anaemia at postpartum (Hb less than 80 g/L) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 4 Supplementation with iron+folic acid versus no treatment/placebo

Outcome: 40 Severe anaemia at postpartum (Hb less than 80 g/L) (ALL)



Analysis 4.41. Comparison 4 Supplementation with iron+folic acid versus no treatment/placebo, Outcome 41 Puerperal infection (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 4 Supplementation with iron+folic acid versus no treatment/placebo

Outcome: 41 Puerperal infection (ALL)



Analysis 4.42. Comparison 4 Supplementation with iron+folic acid versus no treatment/placebo, Outcome 42 Antepartum haemorrhage (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 4 Supplementation with iron+folic acid versus no treatment/placebo

Outcome: 42 Antepartum haemorrhage (ALL)



Analysis 4.44. Comparison 4 Supplementation with iron+folic acid versus no treatment/placebo, Outcome 44 Placental abruption (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 4 Supplementation with iron+folic acid versus no treatment/placebo

Outcome: 44 Placental abruption (ALL)



Analysis 4.45. Comparison 4 Supplementation with iron+folic acid versus no treatment/placebo, Outcome 45 Pre-eclampsia (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 4 Supplementation with iron+folic acid versus no treatment/placebo

Outcome: 45 Pre-eclampsia (ALL)



Analysis 5.1. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 1 Low birthweight (less than 2500 g) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 1 Low birthweight (less than 2500 g) (ALL)

Europe PMC Funders Author Manuscripts



Analysis 5.2. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 2 Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by gestational age at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 2 Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by gestational age at the start of supplementation



Analysis 5.3. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 3 Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by anaemia status at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 3 Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by anaemia status at the start of supplementation



Analysis 5.4. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 4 Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by dose of iron.

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 4 Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by dose of iron



Analysis 5.5. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 5 Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by malarial status of setting.

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 5 Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by malarial status of setting



Analysis 5.6. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 6 Birthweight (g) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 6 Birthweight (g) (ALL)



Analysis 5.7. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 7 Birthweight (g): SUBGROUP ANALYSIS by gestational age at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Europe PMC Funders Author Manuscripts

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 7 Birthweight (g): SUBGROUP ANALYSIS by gestational age at the start of supplementation



Analysis 5.8. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 8 Birthweight (g): SUBGROUP ANALYSIS by anaemia status at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 8 Birthweight (g): SUBGROUP ANALYSIS by anaemia status at the start of supplementation

Europe PMC Funders Author Manuscripts



Analysis 5.9. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 9 Birthweight (g): SUBGROUP ANALYSIS by dose of iron.

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 9 Birthweight (g): SUBGROUP ANALYSIS by dose of iron



Europe PMC Funders Author Manuscripts

Analysis 5.10. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 10 Birthweight (g): SUBGROUP ANALYSIS by malarial status of setting.

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 10 Birthweight (g): SUBGROUP ANALYSIS by malarial status of setting



Analysis 5.11. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 11 Premature birth (less than 37 weeks of gestation) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 11 Premature birth (less than 37 weeks of gestation) (ALL)

Europe PMC Funders Author Manuscripts



Analysis 5.12. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 12 Premature birth (less 37 weeks of gestation): SUBGROUP ANALYSIS by gestational age at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 12 Premature birth (less 37 weeks of gestation): SUBGROUP ANALYSIS by gestational age at the start of supplementation



Europe PMC Funders Author Manuscripts

Analysis 5.13. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 13 Premature birth (less 37 weeks of gestation): SUBGROUP ANALYSIS by anaemia status at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 13 Premature birth (less 37 weeks of gestation): SUBGROUP ANALYSIS by anaemia status at the start of supplementation



Analysis 5.14. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 14 Premature birth (less 37 weeks of gestation): SUBGROUP ANALYSIS by dose of iron.

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 14 Premature birth (less 37 weeks of gestation): SUBGROUP ANALYSIS by dose of iron

Europe PMC Funders Author Manuscripts



Analysis 5.15. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 15 Premature birth (less 37 weeks of gestation): SUBGROUP ANALYSIS by malarial status of setting.

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 15 Premature birth (less 37 weeks of gestation): SUBGROUP ANALYSIS by malarial status of setting



Analysis 5.16. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 16 Neonatal death (within 28 days after delivery) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 16 Neonatal death (within 28 days after delivery) (ALL)



Analysis 5.17. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 17 Neonatal death

Europe PMC Funders Author Manuscripts

(within 28 days after delivery): SUBGROUP ANALYSIS by gestational age at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 17 Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by gestational age at the start of supplementation



Analysis 5.18. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 18 Neonatal death (within 28 days after delivery) : SUBGROUP ANALYSIS by anaemia status at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 18 Neonatal death (within 28 days after delivery) : SUBGROUP ANALYSIS by anaemia status at the start of supplementation

Europe PMC Funders Author Manuscripts



Analysis 5.19. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 19 Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by dose of iron.

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 19 Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by dose of iron

Europe PMC Funders Author Manuscripts



Analysis 5.20. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 20 Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by malarial status of setting.

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 20 Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by malarial status of setting

Europe PMC Funders Author Manuscripts



Analysis 5.21. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 21 Congenital anomalies (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 21 Congenital anomalies (ALL)



Analysis 5.22. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 22 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more) (ALL)

Review: Daily oral iron supplementation during pregnancy

Europe PMC Funders Author Manuscripts

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 22 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more) (ALL)



Analysis 5.23. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 23 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 23 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation

Europe PMC Funders Author Manuscripts



Analysis 5.24. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 24 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation.

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 24 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation

Europe PMC Funders Author Manuscripts



Analysis 5.25. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 25 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron.

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 25 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron

Europe PMC Funders Author Manuscripts



Analysis 5.26. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 26 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting.

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 26 Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting

Europe PMC Funders Author Manuscripts



Analysis 5.28. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 28 Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicators at 37 weeks' gestation or more) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 28 Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicators at 37 weeks' gestation or more) (ALL)



Europe PMC Funders Author Manuscripts

Analysis 5.30. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 30 Side effects (any reported throughout the intervention period) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 30 Side effects (any reported throughout the intervention period) (ALL)



Analysis 5.31. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 31 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 31 Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L) (ALL)



Analysis 5.33. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 33 Infection during pregnancy (including urinary tract infections) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 33 Infection during pregnancy (including urinary tract infections) (ALL)



Analysis 5.34. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 34 Very low birthweight (less than 1500 g) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 34 Very low birthweight (less than 1500 g) (ALL)



Europe PMC Funders Author Manuscripts

Analysis 5.35. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 35 Very premature birth (less than 34 weeks' gestation) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 35 Very premature birth (less than 34 weeks' gestation) (ALL)



Analysis 5.39. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 39 Maternal anaemia at or near term (Hb less than 110 g/L at 34 weeks' gestation or more) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 39 Maternal anaemia at or near term (Hb less than 110 g/L at 34 weeks' gestation or more) (ALL)



Analysis 5.41. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 41 Maternal iron-deficiency anaemia at or near term (Hb less than 110 g/L and at least one additional laboratory indicators at 34 weeks' gestation or more) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 41 Maternal iron-deficiency anaemia at or near term (Hb less than 110 g/L and at least one additional laboratory indicators at 34 weeks' gestation or more) (ALL)



Analysis 5.42. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 42 Maternal Hb concentration at or near term (in g/L at 34 weeks' gestation or more) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 42 Maternal Hb concentration at or near term (in g/L at 34 weeks' gestation or more) (ALL)



Analysis 5.43. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 43 Maternal Hb concentration within 6 wk postpartum (in g/L) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 43 Maternal Hb concentration within 6 wk postpartum (in g/L) (ALL)



Analysis 5.44. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 44 Maternal high haemoglobin concentrations during second or third trimester (Hb more than 130 g/L) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 44 Maternal high haemoglobin concentrations during second or third trimester (Hb more than 130 g/L) (ALL)



Europe PMC Funders Author Manuscripts

Analysis 5.45. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 45 Maternal high haemoglobin concentrations at or near term (Hb more than 130 g/L at 34 weeks' gestation or more) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 45 Maternal high haemoglobin concentrations at or near term (Hb more than 130 g/L at 34 weeks' gestation or more) (ALL)



Analysis 5.46. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 46 Moderate anaemia at postpartum (Hb more than 80 g/L and less than 110 g/L) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 46 Moderate anaemia at postpartum (Hb more than 80 g/L and less than 110 g/L) (ALL)



Analysis 5.47. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 47 Maternal severe anaemia at or near term (Hb less than 70 g/L at 34 weeks' gestation or more) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 47 Maternal severe anaemia at or near term (Hb less than 70 g/L at 34 weeks' gestation or more) (ALL)



Analysis 5.48. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 48 Severe anaemia at postpartum (Hb less than 80 g/L) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 48 Severe anaemia at postpartum (Hb less than 80 g/L) (ALL)

Europe PMC Funders Author Manuscripts



Analysis 5.49. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 49 Puerperal infection (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 49 Puerperal infection (ALL)



Analysis 5.50. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 50 Antepartum haemorrhage (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 50 Antepartum haemorrhage (ALL)

Europe PMC Funders Author Manuscripts



Analysis 5.51. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 51 Postpartum haemorrhage (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 51 Postpartum haemorrhage (ALL)



Analysis 5.52. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 52 Transfusion provided (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 52 Transfusion provided (ALL)

Europe PMC Funders Author Manuscripts



Analysis 5.53. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 53 Diarrhoea (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 53 Diarrhoea (ALL)



Analysis 5.54. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 54 Constipation (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 54 Constipation (ALL)

Europe PMC Funders Author Manuscripts



Analysis 5.55. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 55 Nausea (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 55 Nausea (ALL)



Analysis 5.56. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 56 Heartburn (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 56 Heartburn (ALL)

Europe PMC Funders Author Manuscripts



Analysis 5.59. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 59 Placental abruption (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 59 Placental abruption (ALL)



Analysis 5.60. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 60 Premature rupture of membranes (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 60 Premature rupture of membranes (ALL)

Europe PMC Funders Author Manuscripts



Analysis 5.61. Comparison 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation, Outcome 61 Pre-eclampsia (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 5 Supplementation with iron+folic acid versus folic acid alone (without iron) supplementation

Outcome: 61 Pre-eclampsia (ALL)



Analysis 6.1. Comparison 6 Supplementation with iron+other vitamins and minerals supplementation versus same other vitamins and minerals (without iron) supplementation, Outcome 1 Low birthweight (less than 2500 g) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 6 Supplementation with iron+other vitamins and minerals supplementation versus same other vitamins and minerals (without iron) supplementation

Outcome: 1 Low birthweight (less than 2500 g) (ALL)

Europe PMC Funders Author Manuscripts



Analysis 6.2. Comparison 6 Supplementation with iron+other vitamins and minerals supplementation versus same other vitamins and minerals (without iron) supplementation, Outcome 2 Birthweight (g) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 6 Supplementation with iron+other vitamins and minerals supplementation versus same other vitamins and minerals (without iron) supplementation

Outcome: 2 Birthweight (g) (ALL)



Analysis 6.3. Comparison 6 Supplementation with iron+other vitamins and minerals supplementation versus same other vitamins and minerals (without iron) supplementation, Outcome 3 Premature birth (less than 37 weeks of gestation) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 6 Supplementation with iron+other vitamins and minerals supplementation versus same other vitamins and minerals (without iron) supplementation

Outcome: 3 Premature birth (less than 37 weeks of gestation) (ALL)

Europe PMC Funders Author Manuscripts



Analysis 6.10. Comparison 6 Supplementation with iron+other vitamins and minerals supplementation versus same other vitamins and minerals (without iron) supplementation, Outcome 10 Side effects (any reported throughout the intervention period) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 6 Supplementation with iron+other vitamins and minerals supplementation versus same other vitamins and minerals (without iron) supplementation

Outcome: 10 Side effects (any reported throughout the intervention period) (ALL)



Analysis 6.22. Comparison 6 Supplementation with iron+other vitamins and minerals supplementation versus same other vitamins and minerals (without iron) supplementation, Outcome 22 Maternal Hb concentration at or near term (in g/L at 34 weeks' gestation or more) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 6 Supplementation with iron+other vitamins and minerals supplementation versus same other vitamins and minerals (without iron) supplementation

Outcome: 22 Maternal Hb concentration at or near term (in g/L at 34 weeks' gestation or more) (ALL)



Analysis 6.23. Comparison 6 Supplementation with iron+other vitamins and minerals supplementation versus same other vitamins and minerals (without iron) supplementation, Outcome 23 Maternal Hb concentration within 6 wk postpartum (in g/L) (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 6 Supplementation with iron+other vitamins and minerals supplementation versus same other vitamins and minerals (without iron) supplementation

Outcome: 23 Maternal Hb concentration within 6 wk postpartum (in g/L) (ALL)



Analysis 6.33. Comparison 6 Supplementation with iron+other vitamins and minerals supplementation versus same other vitamins and minerals (without iron) supplementation, Outcome 33 Constipation (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 6 Supplementation with iron+other vitamins and minerals supplementation versus same other vitamins and minerals (without iron) supplementation

Outcome: 33 Constipation (ALL)

Europe PMC Funders Author Manuscripts



Analysis 6.35. Comparison 6 Supplementation with iron+other vitamins and minerals supplementation versus same other vitamins and minerals (without iron) supplementation, Outcome 35 Heartburn (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 6 Supplementation with iron+other vitamins and minerals supplementation versus same other vitamins and minerals (without iron) supplementation

Outcome: 35 Heartburn (ALL)



Analysis 6.36. Comparison 6 Supplementation with iron+other vitamins and minerals supplementation versus same other vitamins and minerals (without iron) supplementation, Outcome 36 Vomiting (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 6 Supplementation with iron+other vitamins and minerals supplementation versus same other vitamins and minerals (without iron) supplementation

Outcome: 36 Vomiting (ALL)

Europe PMC Funders Author Manuscripts



Analysis 6.37. Comparison 6 Supplementation with iron+other vitamins and minerals supplementation versus same other vitamins and minerals (without iron) supplementation, Outcome 37 Diarrhoea (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 6 Supplementation with iron+other vitamins and minerals supplementation versus same other vitamins and minerals (without iron) supplementation

Outcome: 37 Diarrhoea (ALL)



Analysis 6.39. Comparison 6 Supplementation with iron+other vitamins and minerals supplementation versus same other vitamins and minerals (without iron) supplementation, Outcome 39 Placental abruption (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 6 Supplementation with iron+other vitamins and minerals supplementation versus same other vitamins and minerals (without iron) supplementation

Outcome: 39 Placental abruption (ALL)

Europe PMC Funders Author Manuscripts



Analysis 6.40. Comparison 6 Supplementation with iron+other vitamins and minerals supplementation versus same other vitamins and minerals (without iron) supplementation, Outcome 40 Premature rupture of membranes (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 6 Supplementation with iron+other vitamins and minerals supplementation versus same other vitamins and minerals (without iron) supplementation

Outcome: 40 Premature rupture of membranes (ALL)



Analysis 6.41. Comparison 6 Supplementation with iron+other vitamins and minerals supplementation versus same other vitamins and minerals (without iron) supplementation, Outcome 41 Pre-eclampsia (ALL)

Review: Daily oral iron supplementation during pregnancy

Comparison: 6 Supplementation with iron+other vitamins and minerals supplementation versus same other vitamins and minerals (without iron) supplementation

Outcome: 41 Pre-eclampsia (ALL)

Europe PMC Funders Author Manuscripts



Europe PMC Funders Author Manuscripts